Extra Off On Every Report

Healthcare Technology



The global scar treatment market has been examined to pick up a comprehension about the changing situation of the appearance and aesthetic remedial measures. Scar revision is a process that is utilized to limit the scars in a way that they seem more reliable with the encompassing skin tone and skin texture. Scars are unmistakable signs that stay after an injury mends. They are unavoidable aftereffects of damage or a medical procedure and their improvement can be erratic. Scars might be raised or recessed, diverse in toning or texturing from the encompassing solid tissue, or especially perceptible because of their size, shape, or area. Scar treatment industry is creating a quick pace because of the developing awareness among individuals about style, looks and aesthetics. Appearance of different kinds of scars pose an enormous effect on the everyday way of life of the victim, in this way influencing their aesthetic appeal. Henceforth, this factor is anticipated to build up an increased demand for scar treatment. Acne scars standout to be the most widely recognized concerns for women, which upset their aesthetic appeal making them awkward and uncomfortable. Thus, the demand for scar treatment products is estimated to grow rapidly on account of rising concerns for aesthetics.

Growth in number of road accidents likewise results in several skin markets, which numerous a time require careful treatment. Consequently, patients who have experienced such medical procedures are usually given topical items to reduce scars. Corrective medical procedures with laser instruments are likewise being embraced for treating serious scars from road accidents. Postburn marks additionally hamper the every day way of life of a victim. To evacuate these markets, plastic surgeries or re-surfacing laser treatments are widely being performed.

Technically advanced scar reduction products are usually accessible in the market, which limits agony and makes scar treatment an issue free process. These are some of the major aspects anticipated to drive the global scar treatment market.
Rise in revenue produced from the sales of scar treatment items and scar treatment services is directly accounted to the rising personal per capita disposable income levels as well as rising economic growth globally. While treatment of keloids and burned scars is considered as a medically important process by governmental and regulatory bodies, treatment of mild-to-medium acne and spot correction is not considered to be a medical necessity. This might hamper the growth of global scars treatment market over the forecast period.

The global scar treatment market can be segmented on the basis of product, scar type, end use and region. Based on product, the global scar treatment market can be bifurcated into topical products, laser products, injectables and others. On the basis of scar type, the global market can be classified into atrophic scars, hypertrophic and keloid scars, contracture scars and stretch marks.  On the basis of end-use, the global scar treatment market can be bifurcated into hospitals, clinics and retail pharmacies/E-commerce. Based on geography, the market can be categorized into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Some of the major players operating in the global scar treatment market include Enaltus LLC, Merz Inc., Smith & Nephew plc, Lumenis, Mölnlycke Health Care, Sonoma Pharmaceuticals, Inc., CCA Industries Inc., Cynosure, Inc., NewMedical Technology, Inc., Scarheal, Inc. and Suneva Medical, Inc. among others.


The increasing occurrence of diseases in animals as well as the increasing population and in order to surge the animal’s quality of life, the corporations and companies are focusing shifting towards animal stem cell therapies. Animal stem cell market involves the usage of animal’s stem cell in order to treat a disorder or disease. The ability of stem cell is to differentiate into a cell with specific function useful for mending body tissues impaired by injury. The animal stem cell therapy process includes three steps which involve gathering of stem cell sample from animals and then organizing the sample in order to concentrate the stem cells. At last, the therapy involves transferring the stem cells into the damaged site for treatment. The animal stem cell therapy increases the life expectancy of animals and also has no side effects. It is used in treatment, of degenerative joint disorders arthritis, ligaments injuries in animals. The animal stem cell therapy is mostly used to treat dogs, horses, and cats. However the recent innovations in this field have made this treatment possible to use in tiger, pig, etc. The current animal stem cell therapy is considered in treatments of the inflammatory bowel, kidney, heart, liver and immune-mediated diseases respectively.

 The increasing government funding towards protection of animals and rapid approvals of FDA contributing towards the increasing growth of the animal stem cell therapy. The ongoing research in animal stem cells offers a great future for understanding primary mechanisms of animal development. The current ongoing research in this field provides great prospects to treat a broad range of diseases in animals. These factors act as major drivers for the vigorous growth of the animal stem cell market. Based on geographies, North America is dominating the global animal stem cell market due to the rising awareness about the treatment method. U.S represents the largest market share in the North America in the year 2017 due to the increasing demand for the amimal stem cell therapy. Europe and Asia-Pacific are also anticiapted to exhibit significant growth rate during the forecasted period due to the increasing adoption of the animal stem cell therapy. The animal stem cell market in underdeveloped countries is however slow as compared to the developed countries.

Some of the companies in the Animal Stem Cell market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, Vetstem Biopharma, Veterinary Hospital and Clinic Frisco, CO, among others. Several companies are involved in seeking investment from foreign organizations and as well as developing partnerships with the pharmaceutical organizations to strengthen their position in the market. The major companies operating in the global Animal Stem Cell market will eventually grab the opportunity presented by the new technology to further enhance their product offerings.

The global cancer biomarkers market size was valued at USD 10.27 Billion in 2016 and is expected to reach USD 26.80 Billion in 2025, growing at a CAGR of over 11.35% over the forecast period. Increasing demand for cancer detection techniques and requirement of high-speed non-invasive diagnosis using genomics and proteomics are expected to drive the growth of the market over the forecast period.

A biological molecule which is found in blood, other body fluids or tissues indicating the normalcy or abnormality of any biological process, or of a disease/condition etc. is called a biomarker. Cancer biomarkers are molecules, substances or processes indicating the presence of cancers in body. Biomarkers are either secreted by the cancer tissues themselves or are produced as a response to cancer by other cells in the body. They are present in urine, blood, tumor tissue, stool, other tissues or bodily fluids. Myriad of pharmaceutical and biotech companies employ biomarkers during their drug discovery and developmental process. This helps company’s strategic alliances for sharing technology for biomarker applications during large-stage clinical trials which is fueling the growth of the market.

Biomarkers are utilized for follow-up surveillance and early detection of probable recurrent disease in patients who undergo curative surgery for cancer. Besides, incessant advancements in cancer diagnosis employ molecular biomarkers for routine diagnostic tests. Thus, application of cancer biomarkers in a wide range of detection techniques is estimated to impact the market positively.

Rampant cases of cancer across the globe has motivated governments of various countries to focus on investing in developing preventive and early intervention techniques for cancer. Moreover, national healthcare departments are continuously researching on cancer aiming to develop a treatment. Thus, government’s support and innovation and development in the area of cancer diagnosis with biomarker is anticipated to fuel the market growth. However, the steep cost of various cancer diagnostic tests, initial high capital investments, poorly suited reimbursement and regulatory systems and technical setbacks related to sample collection are constraining the growth of this market.

In 2017, breast cancer accounted for the largest market share in the cancer type segment

On the basis of cancer type, the cancer biomarker is classified into breast, multiple myeloma, melanoma, thyroid, liver, prostate, lung, leukemia, colorectal, central nervous system (CNS), bladder, gastric, kidney, and other cancers, such as cervical, non-Hodgkin’s lymphoma, pharynx, pancreatic, oral cavity, stomach and ovarian cancers.

Breast cancer is anticipated to account for the maximum share in the global cancer biomarkers market. Increased focus of key companies on developing novel diagnostic assays is an essential driver for the market growth. Globally, numerous initiatives are being organized for increasing the awareness of breast cancer ensuring early detection of the condition, thereby adding to the number of diagnostic scans. This factor is anticipated to drive market growth of this segment.

In 2017, protein biomarkers are anticipated to dominate the market share in biomarker type segment 

Based on the type of biomarker, the cancer biomarkers market is segregated into genetic biomarker, protein biomarker and other biomarkers. Among these, the protein biomarkers segment is anticipated to dominate the global cancer biomarkers market which can be attributed to the monumental potential of protein biomarkers in detection of cancer, cancer diagnostics, prognostics, and therapeutic & clinical applications. Moreover, unlike steep costs of genetic biomarker tests, protein biomarker tests have low costs. Additionally, key pharmaceutical companies are majorly focused towards discovering protein biomarkers and are anticipated to augment the market during the forecast period.

Geographically, the North America region is leading in cancer biomarker market for the year 2017

The North America region holds the largest market share of the global cancer biomarkers market in 2017 which can be mainly attributed to favorable government policies and increased governmental support in the R&D of biomarkers. Furthermore, surging demand for personalized medicine, adoption of advanced omics technologies for discovery of biomarkers and increased application of biomarkers in drug development and discovery by pharmaceutical companies in the region also aids to the inflating market growth.

Major players operating in the cancer biomarkers market are Abbott Laboratories, Affymetrix Inc., Illumina, Inc., QIAGEN N.V, Agilent Technologies, Thermo Fisher Scientific Inc., Merck & Co. Inc., Becton, Dickinson and Company, Hologic, Inc., Bio-Rad Laboratories, 9F. Hoffmann-La Roche Ltd, Sino Biological Inc., Biomérieux SA, Myriad Genetics, and Quest Diagnostics.

Next Generation Sequencing (NGS), also referred as high throughput sequencing, is a powerful platform that sequences thousands to millions of DNA molecules simultaneously. The global next-generation sequencing market size was valued at USD 3.6 Billion in 2015 and is expected to reach USD 22.3 Billion in 2025, growing at a CAGR of over 20% over the forecast period.

Soaring automation in the pre-sequencing protocols and utilization of novel platforms for developing personalized medicine at a genetic level by prominent industry leaders are significant factors expected to enhance demand for NGS over the forecast period. Moreover, rising inclination of scientists and drug developers towards the NGS technology for implementing the approach of personalized medicine is anticipated to drive the NGS market through to 2025.

Furthermore, growing number of R&D projects in the fields of proteomics, transcriptomics and metabolomics, are also expected to escalate the demand for the technology. Genomics and proteomics studies utilize methods such as sequence determination and subsequent integrated data analysis to assemble and sort an array of structural information produced in these studies. Owing to application of NGS in the above studies, the NGS market is estimated to register growth over the forecast period.

Increasing application in oncology is anticipated to witness lucrative growth during the forecast period owing to the NGS’s rapid sequence development capabilities for allowing oncologists to access genetic information in a relatively less accessible, dense gene clusters. NGS is also equipped with products focusing on complete workflow--from sampling to report generation which can be attributed to NGS market growth. However, lack of skilled technical personnel and accuracy and standardization concerns in diagnostic testing are factors limiting the growth of the market.


Based on product, the market is segmented into consumables, platforms and services. The consumables segment is further divided into sample preparation consumables and other consumables. Further, the sample preparation consumables are further split into quality control, DNA fragmentation, end repair, A-Tailing & size selection and library preparation & target enrichment. HiSeq, MiSeq, Ion Torrent, SOLiD, Pacbio Rs II & Sequel System, and other sequencing platforms are classifications of the Platform product segment. The services segment is also divided into sequencing services which is sub categorized into RNA sequencing, whole exome sequencing, whole genome sequencing, targeted sequencing, chip sequencing, de novo sequencing, methyl sequencing whereas the data management services is categorized in NGS data analysis services, NGS data analysis software & workbenches, NGS storage, management and cloud computing solutions.

The consumables segment held the major market share in 2015 owing to the wide application in the sample preparation and other pre-requisite steps of NGS and is estimated to increase during the forecast period. Increased usage of targeted sequencing owing to associated benefits with a smaller dataset and reduction in sequencing costs accounts for the dominant share in the market.

The application segment is segregated into diagnostics, biomarkers and cancer, reproductive health, personalized medicine, agriculture and animal research and other applications. The diagnostics segment is anticipated to dominate the application segment of NGS market owing to development of NGS-based diagnostic tests by key market players and the increasing adoption of oncology and infectious diseases based NGS-based diagnostic tests.

Based on technology the market is distinguished into sequencing by synthesis (SBS), ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing and other technologies. Increasing demand for Illumina’s systems (including the HiSeq series and MiSeq), development of new and advanced NGS platforms and growing demand for NextSeq & HiSeq X Ten are factors attributing for the largest share of SBS technology in the NGS market.

Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Hospitals & Clinics are a few end user of the market. The hospitals and clinics segment is expected to grow due to the increasing number of agreements between companies and hospitals for developing advanced products and tests in order to cater the requirements of hospitals and clinics.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa and Latin America. In 2017, the North America region commanded the largest share of the NGS market due to the presence of enhanced technological healthcare framework, high R&D investment for genomic and proteomic sequence determination for biomarkers research, and growing adoption of sequencing due to reduced cost per base pair.

Furthermore, Europe NGS market is estimated to grow over the forecast period owing to academic & clinical labs located in the U.S., Germany, and UK. For instance, in June 2015, European headquarters of Illumina Inc. was inaugurated in Cambridge benefit from 10,000 genome project being carried out in UK.

Key companies in the NGS market include llumina, Inc., Thermo Fisher Scientific Inc., Roche Holding AG, Pacific Biosciences, Inc. GATC Biotech AG, QIAGEN N. V., BGI, Oxford Nanopore Technologies, Ltd., Eurofins Scientific, PerkinElmer, Inc., Agilent Technologies, Inc. and Macrogen, Inc.. The companies are focused to tap the market of inexpensive sequencing devices in routine medical checkups. For instance, Grail is developing an NGS technology which is set to launch in 2019 that allows detection of varied types of cancer even before the symptoms appear.


Electronic Health Records (EHR) is an individual's digital health document containing patient’s medical history and is shared among multiple facilities and agencies. The data provides a summary of medical records generated electronically during a clinical encounter, maintained by service providers over time. EHRs comprises of data ranging from progress notes, immunizations, past medical history, laboratory data, demographics, vital signs, medications, problems and radiology reports. EHR's applications are expected to witness growth over the forecast period owing to increasing digital patient information leading to increased demand for mobile access of health record.

The authorized providers are allowed to create and manage the digital information associated with patient health and provide easy accessibility of data to other health care providers. EHRs are built to share information with a range of health care providers and organizations comprising emergency facilities, medical imaging facilities, specialist pharmacies, workplace clinics, school and laboratories.

Medical professionals prefer web based EHR systems due to their reduced deployment costs and automatic backup of data by the vendor thereby increasing EHR’s sales. This software as a service (SaaS) application eliminates technical glitches, allows quick and accurate access of data and  is particularly beneficial to standalone centers or older physicians, who continue to practice with the aim of avoiding penalty charges by the Centers for Medicare & Medicaid Services.

The rising installation of EHR systems can also be attributed to the increasing need for technological advancements and enhancing efficiency in patient care and for secured data. Technological advancement has led to a surge in cloud based EHR software usage, leading to favorable government policies globally, providing financial incentives, hence, boosting the global EHR solution market. However, extremely high cost of EHR and security risks pertaining to patient’s medical history are few constraints of the industry

The Electronic Health Record System market is segmented on the basis of products, into cloud-based software and server-based/ on-premise software. Based on types, the market is fragmented into Inpatient HER and Ambulatory HER. Furthermore, the application segment is bifurcated into clinical application, administrative application, reporting in healthcare system, healthcare financing, and clinical research application. Hospital clinics, specialty centers and others are few end users of the system. Geographically, the EHR market is segmented in five major regions which include North America, Latin America, Europe, Asia Pacific and Middle East & Africa.

North America region is expected to hold major share in terms of revenue owing to favorable government policies, advanced health care facilities and a requirement for health care cost containment. Europe and Asia Pacific regions are also estimated to follow the North American market respectively due to augmented pressure of health care cost containment, increasing geriatric population, growing demand for improved patient care and rising need for remote monitoring. Particularly, the Asia-Pacific region is expected to witness rise in adoption of EHR across various health care centers due to the presence of a large pool of patients, thereby adding to the market growth over the forecast period.

Key player in the Electronic Health Care Solution are GE Healthcare, Medical Information Technology, Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, CPSI and Medical Information Technology, Inc.


Blockchain is known for data-sharing technology and growing interest in the diverse fields for supporting the sharing of data within other industries has led to the application in healthcare industry. The technology works on the lines of a health information exchange system that allows elimination of the friction and cost of current intermediated. It works as a decentralized controller that eliminates the risk of main controller. The Blockchain technology is set to change the ecosystem of the healthcare industry. by utilizing the abilities which include improvement of data security, fighting counterfeit drugs, patient engagement, data sharing, big data analytics, interoperability, health information exchange, R&D processes, AI-based diagnostics and fostering vertical business models.

The healthcare industry has developed the personalized treatment standard owing to increasing pricing pressure for decreasing global healthcare costs and digitization of care delivery models. Increasing myriad of health systems, payers, device and drug manufacturers require a secure and connected health IT ecosystem for managing healthcare data and for promoting value-based care.

Blockchain essentially offers the potential of a shared platform that decentralizes health data thereby ensuring access control, integrity and authenticity of protected health information. Additionally, the blockchain-based distributed network consensus comprises cryptography techniques that provide an additional layer of trust, thereby minimizing cyber security threats for healthcare IT systems. These factors are therefore contributing positively for the industry growth over the forecast period.

Blockchain in healthcare industry is a distributed system which offers privacy, security and interoperability along with recording and storing transaction data to health care data. The design of Blockchain technology allows the non-involvement of central authority and distributes the stored records across all the participants of the network.

Furthermore, major factors propelling the blockchain technology application in health care systems market —include frequently occurring the incidences of deaths due to consumption of counterfeit medicines and limited access to population health data globally. Moreover, the increasing requirement to protect the privacy and security of health information to prevent the data from hacking and attacks further, driving the blockchain technology application in health care systems market. High setup costs and immature infrastructures may restrain the blockchain technology application in health care systems market.

The global blockchain technology application in health care systems market is segmented based on application, end user and region. Based on application, the market is further segmented into precision medicine, clinical trials, electronic health records, and genomics research and drug traceability among others. Increasing transaction between patients, drug manufacturers, pharmacists and wholesalers and necessity for tracking the transaction for verification and secured drug product information is also projected to enhance the industry growth over the forecast period. The end user segment can be further classified into hospitals, pharmaceuticals companies and health care research institutes. Increase in adoption of technological advancements in hospitals and other organizations for providing effective treatment and patient care system is also expected to drive the market.

Geographically, North American region, increase in pharmaceutical crime and technological advancements in the health care systems are the major factors driving the regional market. Increasing government initiatives targeting security medical records of patients are expected to propel the blockchain technology application in health care systems market in Europe. Furthermore, Asia-Pacific region, particularly in China, rapidly growing Internet commerce has also led to an explosion of counterfeit drugs sold thereby driving the market. Increasing awareness for data storage on disease management and minimize expenditure in the health care system in African countries is also projected to spur the industry growth.

Key players operating in the global blockchain technology application in health care systems market are Hong Kong Applied Science and Technology Research Institute Company Limited, BLOCK M.D., Blockchain Health, Guardtime, HealthCombix, Blockpharma, and HASHED Health, among others.


Resorbable implants are prosthetics in nature and are biologically assimilated in the body and is also not required to be removed after a stimulated time. The implants are utilized to regularize the function in the body. The medical device also preserves fixation and gradually decomposes, transferring the stress resulting in healed tissue. The implant degrades in the body via hydrolysis and converts into biocompatible degradation products, which are metabolized by the body. The primary application of the implant is to offer a temporary support to the injured part of the body, allowing it to heal the damaged tissue. Thereafter, the implant disappears gradually post complete fixation and leaves the tissue without any existence of foreign material.

The ability of resorbable implants to eventually assimilate in the body biologically is extremely advantageous, eliminating the long term risks of implantation related complications in the patient. This encourages patients to prefer a biodegradable implant since it can remain in the body permanently and does not require a removal surgery, over a metal implant that might cause pain, wear and tear and a second surgery or a removal procedure. Henceforth, positively impacting the resorbable implant market over the forecast period.

The growth in the global geriatric population dealing with various chronic medical conditions has led to the demand of a safe, fast and effective treatment method for age related medical problems. The application of resorbable factor caters these demands has shown appreciable patient outcome in various orthopedic and dental surgeries. Thus, triggering the demand and application of resorbable implant thereby contributing to the market growth.

Advancement in healthcare industry in the form of sophisticated infrastructure and treatment methods is another factor enhancing the industry growth. However, resorbable implants are made up of polymers that are inherently lower in strength as compared to metals implant rendering them unsuitable for certain cases, constraining the industry growth. Also, high cost for treatment and time consuming approval procedures of implants by regulatory bodies are also expected to hamper the growth of resorbable implants market.

On the basis of product type, the global resorbable implants market is segmented into resorbable band, resorbable mesh, resorbable stent, resorbable scaffolds and resorbable tethers. Based on material type, the global resorbable implant market is segregated into Polylactic acid, Poly-L-Lactic acid, Polyglycolic acid, Poly-D-Lactic Acid, Poly beta Hydroxybutyrate, Polycaprolactone and Polydiaxonone. The application segment is bifurcated into dental surgery, general surgery, vascular surgery and orthopedic surgery. Further, ambulatory surgical centers, specialty clinics and hospitals are few end-users of the market. Geographically, the resorbable implant market is segmented in five regions which include North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

The North American region is estimated to hold the largest share in terms of revenue owing to the stronger health care infrastructure and maximum number of the key manufacturers in the region. Europe region is also predicted to be the largest resorbable implants market post North American region owing to the rise of technological advancement in the region and increasing growth in the geriatric population. Dense population and advancement in infrastructure and technologies pertinent to healthcare is also projected to lead the growth in the Asia Pacific region.

Key companies in resorbable implants market are Johnson & Johnson Services, Inc., Tornier, Inc., Degradable Solutions AG, Bionx Implants Inc., Proxy Biomedical Ltd, Integra Life Sciences Corporation and KLS Martin LP.


Facial Injectables are also referred as Facial fillers or dermal fillers used for rejuvenating facial skin by raising scar depressions, enhancing lips, eliminating/reducing wrinkles and replacing soft-tissue volume loss through facial injections. The injectables include products such as hyaluronic acid, collagen and calcium hydroxyl apatite. and are used to increase the customer’s aesthetic beauty

Changing perception towards the beauty is projected to enhance the industry growth globally. Increasing awareness among consumers for defying the signs of ageing and growing emphasis on physical appearances has led to the consumer spending on facial injectables for cosmetic purposes including reducing deep lines, scar lightening, and easing out wrinkles. However, surgeons prefer facial dermal fillers complementary to face lift instead of various surgical rejuvenation procedures.

The procedure of facial injectables is minimally invasive and hence requires lesser recovery time for aesthetics such as plastic surgeries or face lift. The factor is projected to play a major role in shaping the trajectory of facial injectable market over the forecast period. Furthermore, the procedure is anticipated to gain popularity owing to low instances of postsurgery infections, reduced scarring, lower pain, faster recovery and high accuracy & maximum benefits.

Examples of few commercially available dermal fillers are Restylane (Hyaluronic Acid-Based Filler), Juvederm (Hyaluronic Acid-Based Filler), PREVELLE Silk (Hyaluronic Acid-Based Filler), Hydrelle (Hyaluronic Acid-Based Filler) and others. The increased demand from middle aged & growing urban population and raising esthetic standards are also anticipated to drive the industry growth. The factor also infers that the target age group for such products is men and women aged between 35 to 60 years

The demand to enhance aesthetic beauty and growing number of geriatric population are also responsible for a boost in the industry growth. However, strict regulatory concerns associated with injectable products and side effects of such products such as rashes is expected to restrict the market growth. Various advanced medical procedures such as endoscopy, laparoscopy, arthroscopy and minimally invasive surgeries are also used for facial rejuvenation. For example, in 2014, International Society of Aesthetic Plastic Surgery (ISAPS) reported that more than 20 million surgical and nonsurgical cosmetic procedures were performed globally. In the same year, the number of HA-based surgeries performed was 2,690,633, which then increased to 2,865,086 by 2015.

Geographically, North America region market is projected to acquire major share of facial injectables market where U.S. is expected to hold the largest share in terms of revenue owing to high awareness about aesthetic surgical procedures and increasing number of people opting of aesthetic surgeries. Furthermore, growing demand for younger looking skin in the entertainment industry and organized regulatory framework are also assisting in the industry growth over the forecast period.

Facial fillers are also utilized in indications such as correction of nasolabial folds, lip augmentation, correction of moderate to severe facial folds and wrinkles, dermal implantation, depressed cutaneous scars, cheek augmentation and correction of acne and other such conditions. Asia Pacific region is also expected to drive the market growth over the forecast period owing to the increasing beauty concerns among the mid-age population.

The major key players operating in the market include Merz, Inc., Allergan, Plc, Advanced Dermatology L.P., ColBar LifeScience Ltd., Galderma Laboratories, Sanofi Biosurgery Inc., Anika Therapeutics Inc. and Valeant Pharmaceuticals North America LLC.


The global Assisted Reproductive Technology (ART) market size was valued at USD 21.9 billion in 2016 and is expected to reach USD 36.7 billion in 2025, growing at a CAGR of over 6% during the forecast period. Prevalence of infertility cases caused by lifestyle induced disorders such as obesity and stress is expected to drive the market over the forecast period. Increase in the number of smokers is also anticipated to increase the patient base.

Introduction of enhanced technologies for upgrading the outcomes are also expected to increase the market growth over the forecast period. For instance, in August 2015, a treatment method developed by Ovascience’s named as AUGMENT was reported to rejuvenate the eggs of aging women’s and benefit the poor quality eggs. Another technology named as Vitrification allows direct freezing of gametes with the application of liquid nitrogen and hence, are responsible for increased demand for frozen eggs for further application.

According to the WHO, the rate of fertility per woman has reduced from five in 1960 to 2.5 in 2012. The declining rates of fertility and increasing stress levels are causing physiological problems which have induced a demand for ART procedures, hence, escalating the market growth.

Furthermore, encouraging government and various private organization’s policies for the application of technology is also aiding to the market growth over the forecast period. For instance, multinational companies like Facebook and Apple offer perks to women employees for facilitating the storage of their eggs in order to decrease attrition rate since October 2014. This has enables career oriented women to maintain work-life balance thereby attributing to market growth. Government agencies such as The American Society for Reproductive Medicine (ASRM) has also removed the tag “experimental” from the egg freezing procedure which is expected to draw more customers for the technology, eventually accelerating the growth of segment. Online portals have been created by various industries to share information pertaining to various assisted reproductive procedures contributing to the number of customers of the ART market. 

Based on the technology devised for assisted reproductive health, the market is segmented into in vitro fertilization, artificial insemination, surrogacy and others. Further, vitro fertilization is divided into intra-cytoplasmic sperm injection (ICSI), and preimplantation genetic diagnosis (PGD). The technique artificial insemination is further segmented into intrauterine insemination (IUI) and intracervical insemination (ICI). In-vitro fertilization held the major share in terms of revenue is conducted by utilizing fresh sperm/egg to improve success rates. However, this method was reported to lead to multiple births at times and hence, was rendered disadvantageous. Also, Intracytoplasmic Sperm Injection (ICSI) was introduced for male infertility, wherein single potent sperm is injected into the egg aiding to bring forth more customers thereby leading to market growth.

In terms of procedure, the market is further bifurcated into Frozen Donor, Frozen Non Donor, Fresh Donor, Fresh Non Donor and Embryo Banking. Fresh non donor method is considered as the most advantageous method, since the procedure is relatively less invasive, less expensive and the recipient does not have to go through drug stimulation process. Furthermore, various reimbursement policies have encouraged people to store or donate their gametes. The IVF refund plan designed by Chicago’s Advanced Fertility Center allows 100% refund up to four cycles with fresh embryos. On the basis of end user, assisted reproductive technology market has been segmented into fertility clinics, hospitals and others. The fertility clinics are the most dominating segment owing to the maximum infertility patients opting for the services in the ART market.

Geographically, the global assisted reproductive technology market has been categorized into five major regions and the key countries in the respective region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America region held the major share in the industry owing to increasing prevalence of infertility cases, growing fertility related awareness levels and support of government agencies for in-vitro fertilization. The Europe region is expected to emerge as a leading revenue contributor over the forecast period owing to the rising demand for medical tourism and growing prevalence of infertility. The Asia Pacific assisted reproductive technology market is anticipated to follow European region and is expected to witness lucrative growth owing increasing number poof couples delaying parenthood due to professional commitments, improvement in living standards, and trends towards financial stability.

Major players in the assisted reproductive technology market include Esco Micro Pte. Ltd. (Esco Group), Hamilton Thorne, Inc, CooperSurgical, Laboratoire CCD, Irvine Scientific, Vitrolife AB, Merck KGaA, Nidacon International AB, Nikon Corporation and IncPlaner PLC.


DNA sequencing is the process of determining the sequence of nucleotide bases (i.e. adenine, guanine, cytosine and thymine) in a particular DNA molecule. DNA sequencing techniques ranges from determination of nucleotide sequence of a small length of DNA to entire genome of an organism. The technique is performed by isolating DNA or RNA from archaea, bacteria, plants, animals or various other sources of genetic information. Data acquired is beneficial for various scientific fields, particularly in the field of biology, forensics, medicine and other areas of study. DNA sequencing is umbrella wide term including both Sangers and Non-Sangers method of sequencing.

The technology has enhanced the capability of identification, quantification and functional characterization of the components of the biological networks. Technologies including DNA sequencing provides a bridge between genotype and phenotype of man, model as well as other organisms. Wealth generation of medically relevant information consists in a multitude of human diseases or phenotype is one of the major applications of DNA sequencing. Henceforth, DNA sequencing market is anticipated to form the basis of personalized medicine over the forecast period.

The vendors in the market are catering to the demand of DNA sequencing equipment in the clinical field on account for numerous clinical applications. Next Generation DNA Sequencing (NGDS) is in high demand owing to the novel platforms being developed by coupling with quantum mechanics, nanotechnology, bioinformatics and imaging.

The increasing trends of personalized genomics, oncology research activities, and growing demand for simple and fast clinical diagnosis is expected to spur the industry growth. Moreover, high throughput technology, government aided funding for research activities and various key players investing in DNA sequencing are few drivers boosting the global market. However, repeat sequencing, expensive machinery, requirement of professional expertise and ethical issues are few factors restraining the growth.

The global DNA sequencing market has been segmented on the basis of application, end-user and techniques. On the basis of application, the market has been segmented as forensics, diagnostics, research, personalized genomics, and treatment analysis. Based on end users, the market has been bifurcated as contract research organizations, academic institutions, pharmaceutical industries, hospitals, and diagnostic centers. On the basis of technology used, global DNA sequencing market has been divided as ion semiconductor sequencing, pyro-sequencing, SBS (sequencing by synthesis) technology, sequencing by ligation, single molecule real time sequencing (SMRT), chain termination sequencing, and nanopore sequencing.

North America region is predicted to dominate the global DNA sequencing market followed by Europe and Asia Pacific respectively. The oncology and biomarkers application segment in the region is expected to grow considerably. DNA sequencing is capable of recognizing a broad spectrum of genetic differences and adding to the generation of potent biomarkers in disease diagnostics and medicine. Moreover, time required for sequencing, length of protocol and declining cost of DNA sequencing are few factors making an prospect technology for biomarker discovery and thus are expected to fuel the market.

Some of the key market players in the DNA sequencing market are Roche Holdings AG, Oxford Nanopore technologies, Pacific Biosciences, Eppendorf, Agilent Technologies Inc., Siemens AG Illumina, ThermoFisher Scientific, Genia Corporation and Perkin Elmer.

A biosimilar is a biological medicine, approved by the regulatory bodies based on a high similarity to a pre-existing approved innovative biological product, also referred as reference medicine or originator medicine. The medicine is highly similar, comparable version of an approved biologic medicine. The medicine includes active ingredients identical to the reference small–molecule drugs which differentiates the medicine from generic medicine. Biosimilars are un-identical to the reference biologics including the proprietary details of the reference product and the inherent complexity of biologics. Thus, biosimilars prepared by various manufacturers varies from the reference product making each drug a unique therapeutic option for patients.

Biosimilars are expected to be more affordable therapeutic options based on the complexity, cost of development and manufacture. However, it is not expected to generate the same level of cost savings as generics. Growing demand for biologic medicines is considered to drive the industry growth over the forecast period. Increase in the demand for biosimilar drugs owing to their cost-effectiveness and the rising incidence of chronic diseases are also projected to spur the industry growth.

Increased application of traditional generic drugs and patent expiration of various innovator drugs is expected to be the factors leading to a shift of focus in the pharmaceutical industry towards investment in specialty drugs and high growth areas. Rising life-threatening disorders such as cancer and diabetes with increasing geriatric population has led to the utilization of expensive biopharmaceuticals. Furthermore, governments are switching to affordable alternatives owing to growing emphasis on cost effectiveness and patent expiration of key product classes. Thus, there is a tremendous opportunity for biosimilar manufacturers over the forecast period. However, the development of biosimilar drugs is riddled with complexities. The R&D of the drug, followed by manufacturing and marketing of the drug, is one of the most expensive propositions in the pharmaceutical industry. Patent expiration of biologic drugs over the few years will lead to the acceptance of biosimilar medicine in the industry. According to study, more than 40 biosimilars are under development out of which approximately 20 biosimilars are ready to be released into the market and a significant number of biosimilars are in the pipeline. This will further significantly reduce the costs for patients and health systems. However, the process is anticipated to pose multiple challenges for regulators for confirming the similarity of the biosimilar to the original biologic in terms of efficacy and safety.

The pricing of biosimilar drugs, rising number and quality of tertiary care centers is expected to enhance the application of biotech products, hence driving success in the biosimilars market. The existence of broad range of therapeutic proteins and multiple biosimilar versions of monoclonal antibodies at a relatively low cost in comparison to reference products are also significant factors driving the biosimilar market.

The United States Congress established an abbreviated and distinct pathway for the approval of biosimilars, for recognition of the unique and complex properties of biologics. The pathway requires additional evidence beyond the requirements for generic drug approval, including added analytical characterization and non-clinical as well as clinical data. Owing to the complexities, the development and manufacture of high-quality biosimilars requires manufacturers to have a scientific and manufacturing expertise.

Europe region has been accounted for the largest share in biosimilar market in 2017 and it is expected to be the major contributor to the Biosimilar revenue globally over the forecast period. Growing biotechnology companies in the Asia Pacific region, supported by immense economic development is expected to record a robust growth in biosimilar market over the forecast period thereby making Asia Pacific the major contributor to global biosimilar market. Rising incidence of chronic disorders, patent expiry of biological products, the emergence of new market participants and the launch of new biosimilars are further expected to boost the regional market.

Key players in the biosimilar market include Pfizer, Teva Pharmaceuticals, Sandoz International, Dr. Reddy’s Laboratories, Amgen, Biocon, Samsung Biologics and Celltrion. 


Organ transplantation is a medical procedure which involves removal of an organ from a body and transplanting into the body of a recipient, replacing a damaged or missing organ. Organs may be transported from a donor site or the donor and recipient may be at the same location. Organ transplantation is the last therapeutic option of treatment in the final stage of organ failure. Major organs transplanted are liver, lungs, heart, pancreas, kidney, thymus and intestine. Various organs and tissues including skin, bone, tendons, eyes, heart valves and arteries cannot be donated and can be done post the death of the donor. Tissue donation can also be performed while the donor is alive for cases of bone marrow transplant, removal of amniotic membrane from one’s placenta after giving birth or liver transplant.

Organs and tissue donation can improve a vast number of lives through organ transplant or tissue grafts respectively. Most people can become tissue donors after the death whereas organ donation is specifically done when the donor is still alive. The organ failure occurs owing to several factors such as loss of blood, serious trauma, drug abuse, poisoning, sepsis, leukemia and various other acute diseases. Demand for the organ and tissue transplantation mainly, liver, kidney, lungs, heart is increasing globally. Furthermore, lack of exercise, alcohol consumption, drug abuse, and unhealthy dietary habits also causes organ failure. Increasing incidences for acute diseases has enhanced the number of organ failure. For instance, high blood pressure, diabetes are two very common causes of end-stage rental diseases in which dialysis or kidney transplant are the only treatment for keeping the patients healthy and alive.

Increasing number of tissue banks and introduction of technology advanced products are few major factors spurring the industry growth. However, the huge gap between demand and supply of organ for treatment and shortage of organ donors for transplantation are expected to restrain the market growth. Furthermore, better procurement and harvesting techniques, advance tissue matching and effective anti-infective regimens and vastly improved immunosuppression regimens are also supporting the industry growth. Global organ and tissue transplant & alternatives market has been segmented on the basis of products and regions. On the basis of product, the market has been segregated into tissue typing technology, solid organ procurement and preservation, tissue products, immunosuppressant, post translational monitoring of tissue and organ. Tissue typing technology has been further bifurcated into panel typing and sequencing typing. Furthermore, solid organ procurement and preservation segment has been divided into heart valve, stem cells, and bone matrix products.

North America is projected to dominate the industry owing to well-developed healthcare facilities, and local presence of medical devices and biotechnology companies such as Novartis AG, Medtronic. Europe region is also expected to acquire major share over the forecast period owing to increasing government focus on reforming organ donation policies. Asia Pacific regional growth is anticipated to led by rise in private corporate hospitals with medical equipment and treatment technologies and developing healthcare infrastructure.

Some of the major players in the market of organ and tissue transplantation are Abbott, Arthrex, Bristol-Myers, Biomet, Celera, Centacor and Novartis. Major leading players are involved in developing new products, mergers and acquisitions, and regional expansion for gaining the maximum share in the market.


The global tumor ablation market size was valued at USD 750.4 Million in 2015 and is expected to reach USD 2,129 Million by 2025 growing at a CAGR of over 11.2% during the forecast period. The market growth can be attributed to increase in cancer cases globally over the forecast period. Increased procedural safety profile, technological advancements in the field of healthcare, and growing number of public-private initiatives is further expected to spur the market growth. 

Furthermore, rising demand of minimal invasive tumor ablation techniques, & funding to support ongoing research activities related to tumor ablation are also responsible for the surge in tumor ablation market. According to the World Health Organization (WHO), about 13% of the people suffer from cancer across the globe. Additionally, it is also estimated that there will be a 70% rise in cancer cases and more than 100 cancer types will require tumor ablation, thereby boosting the market growth over the forecast period.

The geriatric population is also expected to double in numbers and the global population will also have anticipated to increase from 12% to 22% from 2015 to 2050, based on a WHO report. The demand for minimally invasive surgeries (MIS) is rising with the increasing geriatric population since, patients experience lesser trauma in MIS and recover faster as compared to invasive procedures. Minimally invasive surgeries such as radiofrequency ablations is highly demanded and hence, is responsible for the market growth. Additionally, government and various healthcare agencies are actively creating awareness about various cancer types, accentuating the usage of tumor ablation therapy.
Furthermore, High Intensity Focused Ultrasound (HIFU), laser ablation and irreversible electroporation are few techniques which are projected to grow clinically, simultaneously propelling the tumor ablation industry. The increased per capita income in developed as well as emerging nations is encouraging people to undergo advanced therapy for tumors, thus further assisting market growth. Although, cost containment adopted by various governments and unfavorable regulatory policies may act as a constraint to the industry growth.

The tumor ablation market is segmented on the basis of technology, treatment, application and region. Based on technology, the market has been segmented into cryoablation, microwave, radiofrequency and other technologies which include HIFU, radio iodine and laser ablation. In 2015, radiofrequency tumor ablation technology segment held the maximum share in the tumor ablation market. Radiofrequency ablation is increasingly utilized in solid tumor excision owing to the enhanced efficiency and specificity towards the method, thereby contributing majorly to the market growth.

Microwave ablation technology is anticipated to witness a substantial growth over the forecast period. The segment’s growth can be attributed to the benefits associated with the technology such as consistency in high temperature, optimal heating of the cystic mass, larger tumor ablation volume, reduced procedural pain and lesser ablation time. Improved efficacy with minimal complications and reduced hospital stay are further expected to drive growth of the segment.

On the basis of treatment, the market is segmented into percutaneous procedures, surgical procedures and laparoscopic procedures. Percutaneous procedures are expected to exhibit massive growth over the forecast period owing to the rising demand for minimally invasive surgeries which offers faster recovery, less scarring and more safety. However, increased complications, post-surgical discomfort, and gradual recovery are a few restrains holding the market back.
Percutaneous ablation is anticipated to witness enormous growth due to the simple and technologically advanced procedure used to treat the tumors. The procedure terminates the tumor in target tissues quickly and saves time, allowing faster recovery and ultimately leads to growth of the segment.

The application segment is segregated into liver cancer, breast cancer, lung cancer, prostate cancer, kidney cancer, bone metastasis and ENT cancer. Increasing cases of cancer is expected to assist the growth of tumor ablation therapy industry. Lung cancer is anticipated to grow with the highest CAGR over the forecast period. Increasing number of cases of lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC) utilizes radiofrequency ablation technology leading to the major application.

North America region dominated the global tumor ablation market in 2015. Factors contributing to the regional growth includes availability of reimbursement, government support for quality healthcare and increasing prevalence of cancers in the U.S. and Canada, and high purchasing power parity. For instance, Patient Protection and Affordable Care Act (PPACA), also known as ObamaCare, promotes quality and affordability of health insurance and reduces the cost of healthcare for individual and government. Such government initiatives help in improving the overall healthcare system, thus boosting growth of tumor ablation market.

Europe regional market is accounted for a substantial share in the global tumor ablation market which can be attributed to Europe’s publically funded healthcare system. Growing geriatric population base coupled with the support of government policies aiding in controlling cancer lead to substantial industry growth of the region.
Furthermore, Asia Pacific region is also anticipated to witness a lucrative growth over the forecast period owing to improving healthcare infrastructure with various government initiatives aiding market growth. Economically developing countries such as India and China are expected to aid the market growth owing to a huge population base.

Key players of tumor ablation market inlcude Covidien, HealthTronics, Galil Medical Inc., Angiodynamics, Misonix Inc., Medtronic Plc., SonaCare Medical, Boston Scientific Corporation, Neuwave Medical Inc. and EDAP TMS S.A. Key players along with certain new entrants in the market, namely-- Covidien, Plc, Medtronic, Inc., SonaCare Medical, LLC and NeuWave Medical, Inc. are investing heavily to strengthen the R&D capabilities for developing the novel tumor ablation products and to expand the clinical application profile of their existing tumor ablation products.


Artificial organs are manmade device or organs integrated into the human body to replace the functions performed by the natural organs and empower patients to return to a normal life. The unnatural devices or machines are utilized in case of human organ malfunction or organ failure. The manmade devices are usually produced from the stem cell of the respective patients and grown in laboratories in controlled environment. Increasing development and innovation of new artificial organs are gradually progressing promising a positive growth prospect to the global market over the forecast period.

The demand for organ donor is increasing owing to the vast gap between the demand and supply of organs to patients. Estimation shows that only 10% of the patients who require a transplant undergo the necessary procedures due to the scarcity of donor organs. More than 119,000 patients in the United States alone were on the waiting list for organ transplantation in 2015. According to the study conducted based on the market, approximately 22 patients die owing to the lack of available organs for transplantation. It was estimated that Europe had more than 143,000 patients on the waiting list for organ transplantation by the end of 2015. Lack of organ for transplantation is responsible for the death of around 18 patients each year in Europe.

Increasing organ failure owing to the age-related disorder and new and improved technologies are few drivers expected to offer opportunities to propel the market growth. The ability of the device to completely replace the human organ and the tendency to retain the normal functioning of organs, temporarily or permanently is also anticipated to spur the industry growth. Since, increasing chronic disorders has led to affect the one or multiple vital organs leading to the increasing demand of the organs.

Incidences of organ failures and lack of potential organ donors is responsible for loss of lives of patients suffering from such crisis and henceforth, has led to the increase demand for the artificial organ’s market. Growing incidences of severe injuries caused due to accidents and acceptance of organ transplant as a successful treatment method globally are other factors fueling the market growth. Furthermore, rising life expectancy, increasing healthcare awareness among population and growth in geriatric population are considered as the important driver for the growth of artificial organs market.

Wearable artificial organs such as pancreas and kidney have created a substantial customer base and thus, is expected to boost the demand over the forecast period. The rising pool of patients suffering from renal failure/dysfunctioning and diabetes will also particularly foster the demand for artificial kidney and pancreas respectively. Additionally, with the advent of the wearable medical device technology, more cost effective organs are expected to arrive in the market which could open new doors for the emerging economies. One of the major constraints for the artificial organ market is the extremely high cost of the artificial organs. This in turn is responsible for various production policies required to address the taxpayers, patients and medical technology corporations.

Consumers are hesitant to buy the organs owing to the possibility of device malfunction and the consequences they may have on their respective health, which could impede the growth of artificial organs market. Prosthetic devices such as brain pacemaker have very slim chances of being repaired or restored by artificial organs and due to their unaffordable costs, consumers usually opt for other affordable treatment method. Policies such as uncertain reimbursements and lower awareness about the associated surgical procedures are expected to restrict the market penetration over the forecast period. Furthermore, maintaining the quality and efficiency of artificial organs for a long period of time is a major challenge for the medical sector and thus, could further deter the artificial organ growth.

North America is expected to acquire the major share in the artificial organ market, followed by Europe. However, Asia Pacific countries is expected to observe significant growth which can be attributed to growing healthcare budget, improving healthcare infrastructure and flourishing medical tourism. Key players in the artificial organ market include Biomet, Inc., ABIOMED, Inc., Berlin Heart GmbH, Asahi Kasei Medical Co., Ltd., Ossur hf, Cochlear Ltd., Thoratec Corporation, HeartWare, Inc., Edward Lifesciences Corporation, Jarvik Heart Inc., Boston Scientific Corporation, Touch Bionics and Lifenet Health.


Corporate wellness entails organizational policies designed to support healthy behavior in the corporate organization, promotion of health related activities that improve health outcomes. Most of the modern corporate workforce leads a desk-bound lifestyle. However, a significant number of employees has been recorded to suffer from various diseases including hypertension, obesity, depression diabetes, and cardiovascular diseases leading organizations to spend considerable amount of resources on human resource management. Corporate wellness initiatives were taken on as a solution and focuses to improve and maintain employees’ health.

Absenteeism is one of the major factors diminishing the productivity of a company and impacting companies’ profits. Corporate wellness programs help companies in reducing attrition rate and absenteeism, thereby increasing overall productivity of the company. Improvement in employee well-being by motivating employees at work place, organizing regular fitness activities and helping in lowering the overall healthcare costs.

The industry involves psychological therapists, fitness and nutrition consultants, and other organizations providing similar services. As per Harvard Business Review, companies receive an average return of $2.71 for $1 directly into corporate wellness investment, achieved through reduced healthcare costs, lower absenteeism and higher productivity. Similarly, in Glasgow City Council (GCC), employee absenteeism reduction through workplace wellness programs, saved millions. Under the corporate wellness program, the company rehabilitated employees who were on a long-term sick leave. This in turn, speeded up the medical appointments and the staff was being treated promptly. Within a year, absenteeism related sickness dropped down to 8.1 days from 12.5 days, saving the company USD 12.9 million. In the following year, the number dropped down to 7.4 days per employee on a sick leave, saving another USD 4.9 million for the company.

In the U.S., government introduced Affordable Care Act increased the incentives from 20% to 30% for the employees participated in wellness programs pertaining to health. Thus, implementing corporate wellness programs is beneficial to the profit percentage of the company and the added benefit of better health services increase the employee retention percentage of the company. Furthermore, corporate wellness program motivates employees to perform better and promotes employee satisfaction across the workforce.

Corporate wellness programs were implemented in larger organization which could afford the programs. However, smaller organizations have increasingly started adopting such programs, expected to propel the market rapidly. Emerging countries including India and China are witnessing an increase in industrialization which could also support the market growth. Even employers are more committed to improve health of the employees for maintaining a work health balance. Lifestyle coaching, biometric screenings, gym services within the company premises, free health check-ups, healthy snacks, and health clubs, synchronize hospital care by service providers are few activities conducted in wellness program.

The availability of favorable regulatory scenarios (e.g. - Accredited program of Wellness & Health Promotion (WHP) by the National Committee for Quality Assurance (NCQA)) is identified as one of the primary growth factors for the market and will support the need for corporate workplace wellness during the forecast period. According to the Global Wellness Institute, the industry is already worth over $40 billion. Even so, only 9 percent of the global workforce has access to some form of workplace wellness program. Consequently, there’s are huge market opportunities for corporate wellness solution providers over the forecast period.

Promotion of health and well-being are driven by increase in NCDs, government support and initiatives, and increasing number of white collar employees are few drivers spurring the global market. Moreover, factors including rising health consciousness, mandatory law to incorporate corporate wellness services, and willingness of employers to invest in wellness programs are also anticipated to increase the demand. Although, major restraint includes inefficient execution of services, lack of efficient and effective models and increased costs for the companies. Availability of time for leisure and recreation paves as the major opportunity for the services expansion over the forecast period.

The global corporate wellness market has been segmented by services offered. Based on services, the market has been segregated as health risk assessment, fitness, smoking cessation, health, weight management, nutrition corporate, and others. The smoking cessation segment is projected to expand at an impressive CAGR during the forecast period. An estimated 5.8 trillion cigarettes were consumed globally in 2014 and the consumption is still increasing. China ranks first in the top ten countries in terms of cigarette consumption. Other countries include other countries in Asia Pacific such as Indonesia, Japan, India, and South Korea.

North America and Europe-based companies have accustomed the companies with the concept of corporate wellness. However, Asia Pacific market especially holds potential as being an emerging market, global companies are trying to build their hold in these regions. The corporate wellness market is characterized by the presence of numerous international and regional vendors. The regional vendors are finding it difficult to compete in the market owing to the presence of international vendors having an upper hand in quality, pricing, financial resources and market research. As the product’s demand increases, the competitive environment in the market will intensify further

Some of the key players in the corporate wellness market include, Trotter Wellness, GCC Group, Wellness Corporate Solutions, Fitbit,, Well Nation, FitLinxx, Virgin Pulse, ComPsych, EXOS, Kinema Fitness, Provant Health Solutions, Karelia Health, Marino Wellness, Wellness Corporate Solutions, WorkStride, Premise Health, Vitality, Wisdom Works Group and Wellsource, as the key vendors in the global corporate wellness market.

The global Point of Care (POC) Diagnostic market was estimated as USD 15.4 billion in 2015 and is anticipated to reach USD 28.7 billion by 2025 growing with a CAGR of over 6% during the forecast period. Emerging technological advancements in biosensors, smartphones, wearable devices and lab-on-a-chip are transforming the point of care diagnostic market. The POC diagnostics industry has been expected to be a part of paradigm shift from curative medicine to predictive, preemptive and personalized medicine.

POC diagnostic tests are either antibody-based or microbial particle-based, assisting in decreasing the interval between diagnosis and treatment of a disease. Healthcare professionals collect the testing samples from the patient, analyze and record the result. A POC diagnostic test embraces Enzyme-Linked Immunosorbent Assay (ELISA), lateral flow immunochromatography, and agglutination tests. High prevalence of infectious diseases in emerging nations, increasing preferences for home healthcare option, and rising incidences of target diseases across the globe are few factors gaining the traction of POC diagnostic products globally. 

Furthermore, increasing chronic diseases, rapid upsurge in the aging population, and rising consumer awareness are also positively influencing the POC diagnostic market. It has been expected that the number of cellphone users have passed 7.4 billion in emerging countries and the population in the countries is marred by various communicable/non-communicable diseases. Henceforth, Point-of-Care Diagnostics has been predicted to be a revolutionary aid in treatment procedures and projecting emerging countries to be a highly profitable market for POC Diagnostics.

Additionally, technological advancement, increased R&D expenditure on novel products, and rapid economic development in the emerging nations owing to low penetration level of POC diagnostics are few other driving factors for the growth. However, product recalls, unfavorable reimbursement scenario and stringent regulatory framework are considered to be themajor hurdles altering the POC diagnostics expansion.

Based on product segment, the POC diagnostic market has been bifurcated and the report displays the market share, growth and revenue of each type:

•    Glucose Monitoring.
•    Cardiometabolic Testing
•    Infectious Disease Testing
•    Coagulation Testing
•    Pregnancy & Fertility Testing
•    Tumor/Cancer Marker Testing
•    Urinalysis Testing
•    Cholesterol Testing
•    Cholesterol Testing
•    Hematology Testing
•    Drugs-of-Abuse Testing
•    Fecal Occult Testing
•    Other

Some of the major end-user for the global POC diagnostics market has been segregated as:

•    Professional Diagnostic Centers
•    Hospitals
•    Home Care
•    Clinics
•    Others

Home care segment is anticipated to hold at the highest rate over the forecast period

Clinics segment has been projected to hold the largest market share with respect to revenue generation owing to substantial number of Clinical Laboratory Improvement Amendments (CLIA) -waived tests are implemented within clinics. Furthermore, decentralization of primary care services in several regional markets around the world has become a common trend, significantly positively impacting the future progress.

Additionally, easy-to-use POC devices availability in out-of-hospital laboratory settings has resulted in the significant share of the segment. Furthermore, government bodies, such as National Health Service (NHS), are undertaking POCT-based initiatives and schemes to reduce the pressures on frontline care. POCT initiatives have stimulated the primary care settings, such as clinic, to adopt POCT services for diagnosis of various diseases. However, home care segment has been expected to emerge as the fast-growing segment over the forecast period. Growing concern for initial detection and elimination of any chronic condition occurrence is predicted to drive the segment growth over the forecast period.

Geographically, the global POC diagnostic market has been segregated into North America, Europe, Asia Pacific, the Middle East and Africa and Latin America, market share¸ with revenue (Billion USD), and growth rate for these regions, from 2015 to 2025 (forecast)

•    North America: U.S., Rest of North America
•    Europe: Germany, France, UK, rest of Europe
•    Asia Pacific: China, Japan, India and Rest of Asia Pacific
•    Middle East & Africa: GCC, South Africa, North Africa and Rest of MEA
•    Latin America: Brazil and Rest of Latin America

North America region has been expected to hold the major market share owing to the rising geriatric population base and the presence of higher healthcare expenditure levels. Furthermore, high awareness amongst physicians and patients coupled with early disease diagnosis support the largest share of region in the industrial revenue.

Asia Pacific region is estimated to grow with fastest CAGR over the forecast period since, the companies in the region are engaged in capitalizing the untapped potential in the region to enhance market position. Additionally, growing awareness for rapid disease detection to improve the patient survival rate is expected to boost the POC products.

Some of the prominent players operating in POC diagnostic market include Abbott Laboratories, bioMérieux SA, Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.), Abaxis, Siemens, EKF Diagnostics, Danaher, Instrumentation Laboratory, Healthineers, Nova Biomedical, Quidel Corporation, Trinity Biotech, Chembio Diagnostics, Sekisui Diagnostics LLC, Trividia Health, Inc., OraSure Technologies Inc, Becton Dickinson & Company (BD), and Johnson & Johnson Services, Inc.


Prosthesis is an artificial device capable of replacing a body part lost due to congenital conditions, trauma or diseases. The primary purpose is to perform functions accomplished by the missing body part. Prosthesis is usually created with Computer Aided Design (CAD) visualizing the 3D design and major application is to enhance the function and lifestyle of persons with limb loss.

Prosthetics customers are patients experienced amputation due to risk factors such as accidents, frostbite, abnormalities in blood vessels or nerves, cancer, trauma, infection or born with limb deficiency. Obesity, diabetes, stroke, and arthritis are few diseases contributing to the increasing number of globally amputation cases. Prosthesis is customized based on the appearance and functional needs of the customer. There is a range of prosthetics varying in materials used, alignment, design and construction. Amputee Coalition published a report stating that approximately 185,000 amputations are performed in the U.S alone each year henceforth, paving new market growth to witness the demand over the forecast period.

The aim for future designs of prosthesis is to develop extremely powerful and much more realistic looking products, particularly for patients who are likely to have their artificial limb exposed. The field of prosthetics is also venturing into making exoskeletons .Exoskeletons are artificially intelligent, bionic devices that can be worn by wheelchair users and the device will help them to walk again. Prosthetics have moved on from simple aesthetic replacements to an addition which functionally capable of performing everything that a biological limb can do. Thus as time passes, prosthetics are getting smarter.

One of the most crucial factors aiding to the rising demand of prosthetic devices is involvement of government agencies such as Centers for Disease Control and Prevention (CDC) and Defense Advanced Research Projects Agency (DARPA). Both of these agencies are funding research for development of limb prosthetics. Other factors driving the market demand includes advancement in technology, increase in the number of amputation cases both due to accidents as well as diseases and wars. Particularly myoelectric prosthetics segment is expected to grow considerably owing to advanced technology that allows patients more freedom and mobility while using their limbs.

The global prosthesis market has been segmented by technology and extremity. On the basis of extremity, the market segment has been further segregated as upper-limb and lower-limb prostheses. Upper limb prosthesis addresses activities such as grasping and reaching, painting, hammering, weight lifting and other activities of daily living like drinking/eating, dressing and writing. Lower limb prosthesis provides stability while standing and walking, absorption of shock, cosmetic appearance, and even jumping, kicking, running and many such other athletic activities.

Lower body extremity segment is expected to hold majority of the revenue share owing to the huge commercial presence and large number of lower body amputation cases across the globe. Furthermore, the lower body segment is anticipated to grow at the significant rate owing to rising prevalence of vascular disease and diabetes, further leading to a rise in the number of lower limb amputation.

Technologically, the global prosthesis market has been divided into Microprocessor Controlled (MPC) prosthetics and myoelectric prosthetics. MPC prosthetics has been anticipated to account for the maximum revenue share over the forecast period owing to the application of novel devices implementing MPC technology. Few MPC devices commercially available are Knee Joint C-Leg, PROPRIO, RHEO KNEE, Elan, and Plie.

Prosthesis manufacturing companies use the most advanced technologies such as Bluetooth, microprocessor controller, and myoelectric technology along with the lightest material to manufacture various prosthetic products. Prostheses can also be controlled by microprocessors and nerve impulses has given rise to highly advanced prosthetics for converting muscle movements to electrical signals and vice versa thereby, improving the overall efficiency of devices. Standard Grade Polypropylene plastic or thermoplastics and carbon fiber are used to allow artificial limbs to be light-weighted, yet extremely strong, such that no additional energy is required to operate that particular limb. Rising awareness and increased adoption of these technologically advanced products particularly in developed regions are few factors expected to boost the market over the forecast period.

North America region is predicted to witness acquire the major revenue share followed by Europe. Growing healthcare expenditure, increasing technologically advancements, surging amputee population, and favorable government initiatives for robotic technology are few key drivers for the growth in the region. However, Asia Pacific is anticipated to rise at the fastest rate over the forecast period owing to rapid economic development, high diabetic population, rising geriatric population, and developing healthcare infrastructure in countries such as India, Indonesia, Philippines, and China. Increasing number of amputees and incidence of foot ulcers associated with diabetes drives the market for robotic prosthetics.

Research and Developments initiatives have been taken up by key players of the market which promises a lucrative growth rate in market over the forecast period. Some of the key players include Touch Bionics, Inc., Oessur Americas, SynTouch, Inc., Ottobock, Shadow Robot Company, Endolite and HDT Global.


Cryotherapy or cryosurgery is the science that involves subjecting the body to sub-zero temperatures in order to stimulate physical and mental health benefits. Cryotherapy is capable of boosting blood circulation throughout the body resulting in a caloric burn rate and a higher metabolic rate. Cryotherapy also leads to the increment in the level of endorphins which elevates the mood and reduces stress. Major application of cryotherapy is in dermatology to relieve muscle pain, sprains and swelling for soft tissue damage or postoperative swelling. Cryotherapy also increases collagen production giving a tighter, more youthful and glowing skin.

Various benign and malignant lesions are treated by using cryotherapy as an in-office procedure. The mechanism of destruction in cryotherapy is necrosis, which results from the freezing and thawing of cells. Freezing and thawing causes reduction of inflammation in the body due to a boost of an anti-inflammatory chemical called norepinephrine.

Growing popularity of cryotherapy for treatment of various cancer and musculoskeletal conditions, including arthritis, basal cell skin cancers, Bowen disease, rheumatic conditions, and fibromyalgia, is one of the major factor anticipated to propel the market growth. In addition, ease of application and low cost involvement has also spurred the sector growth over the forecast period. Spray freeze technique, the applicator technique, cryoprobe method and thermo-coupler method are few of the techniques utilized across the globe for various ailments. Furthermore, Cryotherapy has wide application in novel methods including selective cryolipolysis and Whole Body Cryotherapy (WBC). Selective cryolipolysis processes fat cells to near-subzero temperatures. Whole Body Cryotherapy (WBC) method exposes body to extremely cold temperature ( -140 °C) for a period of a three minute, enhancing performance, recovery, beauty, wellness, beauty, and weight loss benefits. WBC has been used by various sportsmen and fitness enthusiasts.

Although, cryotherapy is not considered as the best modality for treatment for most of the lesions, however, it is the first line treatment and a valuable alternative for cancers patients. Overall, cryotherapy is a safe and easily usable treatment method for destroying many benign and malignant lesions.

The global cryotherapy market has been segmented by therapy type, by device type, and by application. Based on therapy type, the market has been bifurcated as cryosurgery, icepack therapy, and chamber therapy. On the basis of device type, cryotherapy sector has been segregated as cryoguns, cryoprobe, gas cylinders, cryochambers, gas pressure gauges, and thermocouple devices. Major applications for the cryosurgery market are oncology, ophthalmology, dermatology, cardiology, pain management, and gynecology.

Oncology segment has been anticipated to witness the highest revenue share owing to rising prevalence of cancer and increasing awareness of cryotherapy-based treatment practices. Cryogenic gases are implemented to treat various cancers of prostate, cervical, skin, and lungs. As per WHO report, cancer is one of the leading causes of mortality with over 8.2 million cancer-associated deaths and the number of new cancer cases is projected to rise by 70% over the next 2 decades. The cryotherapy demand has been predicted to propel owing to the upward trend in the incidence and prevalence of cancer over the forecast period.

North America market has been projected to dominate the regional sector owing to advanced healthcare infrastructure. Well-established healthcare infrastructure and high per capita healthcare expenditure in the U.S has anticipated to drive cryogenic gases application for therapeutic purposes. Moreover, availability of cryoprobe, cryoguns, and other advanced products are estimated to drive the demand.

Asia Pacific region has expected to exhibit the highest growth rate over the forecast period due to untapped opportunities in the region. Furthermore, patient awareness of cryosurgery for cancer and skin treatments coupled with the rapidly developing healthcare infrastructure in the emerging Asian nations has predicted to enhance the growth.

Cryotherapy is a growing market delivering various opportunities for the healthcare sector and has attracted a large number of target audience. Various venture capitalists, niche companies manufacturing cryoablation/cryotherapy systems, research and consulting firms, cryotherapy equipment manufacturers and distributors, healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies), medical device vendors/service providers and research institutes are actively implementing cryotherapy.

Various global companies have already entered cryotherapy market with the growing audience in the industry. Some of the major players include Medtronic (Ireland), Galil Medical (US), Zimmer MedizinSysteme (Germany), Cooper Surgical (US) and Impact Cryotherapy (US).

Point-of-care Diagnostic (POCD) is defined as medical diagnostic technology that can be used at the point of care i.e. wherever the patient is present. The diagnostic technique is very different from the traditional testing methods. In traditional diagnostic tests, the diagnostic tests were performed at their respective laboratories and patients had to wait for days for the results, point-of-care diagnostic involves bringing the diagnostic tools immediately and conveniently to the patient and providing rapid diagnosis in real time.

The driving notion of point-of-care diagnostic is its quick diagnostic techniques which allow faster treatment, medication and clinical management based  on the POCD results.. Point-Of-Care Diagnostics includes development in microfluidic, biosensors, assay formats, bio-analytical platforms, lab-on-a-chip technologies and complementary technologies.

Point-of-care diagnostic gathers the specimens and procure results in a short span of time, essentially near the location of the patient such that the cost of treatment is cheaper, quicker and more precise. From management of patient’s data to diagnosis and monitoring of a disease, POCD facilitates all of the tasks for a patient requiring rapid detection. 

POCD also plays an important role in patient management, reducing the time required to treat an ailment and improves the ultimate outcome of patient’s health. Since, there are a vast number of point-of-care assays i.e. assays performed on patients, various biomarkers have been developed by deploying portable and simple in usage point-of-care clinical and biochemical analyzers. This is considered to be a revolutionary for many diseases, particularly the ones that require immediate assistance like ischemic stroke. Even for various other diseases, treatment and medical intervention at an early stage would be responsible for saving a lot of lives.

Some examples of equipment being used for improved Point-Of-Care Diagnostics includes label-free biosensors such as white light reflectance spectroscopy (WLRS) and Surface Plasmon Resonance (SPR). Complementary technologies such as system integration, microfluidics, lab-on-a-chip technologies, signal readout and device automation are propelling the Point-Of-Care Diagnostics towards continuous improvements over the forecast period.

Point-Of-Care Diagnostics disposed towards smart devices equipped with mobile healthcare (mH) is predicted to be the major trend in the market, since, this could be particularly revolutionary for POCD and personalized healthcare monitoring and management. Many promising mobile healthcare technologies have been developed that are being used for a readout of colorimetric, lateral flow, electrochemical, fluorescent, chemiluminescent , label-free assays, detection of cells, biomolecules, nanoparticles, and microorganisms and other diagnostic applications using the cellphone-based POC technologies. 

It has been estimated that the number of cellphone users have passed 7.4 billion in emerging countries which is 70% of the total cellphone users and the population in these countries is marred by various communicable/non-communicable diseases. Hence, Point-Of-Care Diagnostics could be a revolutionary aid in treatment procedures in the region. Therefore, emerging countries is projected to be a highly profitable market for Point-of-Care Diagnostics.

Some of the major stakeholders in the Point-Of-Care Diagnostics market include various medical device manufacturing companies, companies distributing POCD equipment, clinical laboratories, hospitals, clinics and special areas such as sports and military fitness bodies, government /private research institutes and clinical research organizations (CROs). Establishment of an international cloud for ease in management of Big Data may hinder the market over the forecast period, since, the technology requires personal data of patients, therefore, effective measure would be required for security of privacy of data storage. 

The POCD market is set to witness a rise owing to a global demand of a technology facilitating self-monitor and management of the personal health. Roche (Switzerland), Abbott (US) and Siemens (Germany) are the prominent players in Point-Of-Care Diagnostics acquiring the major share in the industry. Various other companies like Instrumentation Laboratory (US), Nova (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Quidel (US), EKF Diagnostics (UK), Chembio Diagnostics (US), Trinity Biotech (US), and AccuBioTech (China) are set to enter the market with their respective products for Point-of-Care Diagnostics.


Smart healthcare products are an innovative solution for various complexities faced by healthcare industries. It comprises a range of products that are low power, wirelessly connected, intelligent and efficient. Patients and healthcare providers are equipped with interactive and customized healthcare materials from disease diagnosis and treatment to online access to medical records by implementing ICT technologies. Smart Healthcare solutions are also capable of interfacing with hospital systems, viewing medical records, appointment scheduling, waiting lists for hospital appointment and information regarding previous medication records on mobile devices. These services are applicable to a wide range of areas which include hospital directory and online patient consent, self-diagnosis, location-based hospital assessment information, medical examination result view and health management.

Smart Healthcare Products shall be powered by Internet of Things and the result of the usage could be revolutionary for the healthcare industry. For instance, patients will have access to products that reminds sick people to take their medicine along with instructions pertaining to dosage and time intervals as well. Virtually every part of the body could be monitored with the respective sensors that will send critical vital signs to centralized systems. Furthermore, patients who cannot afford to go to the hospital will have access to devices that are capable of providing diagnostic reports actively.

The smart healthcare product segment is expected to grow substantially owing to the use of big data solutions and analytics, electronic health records which will transform healthcare-related processes into an efficient, precise and quick process. The soaring costs of premium healthcare are compelling people to choose proactive health monitoring options and low-cost alternatives over traditional healthcare providers and services. Consumers are actively looking into a health-management ecosystem that is supported by Internet of Things and can cater to their respective needs.

The technologies assisting the consumers in gaining better health conditions are already apparent. For instance, a smart watch called MOTIO HW has been designed to help consumers fight sleep apnea; a heart monitor called QardioCore gives information on heart rate, activity levels, ECG, skin temperature, and respiratory rate and a smart glass namely Aira helps visually impaired people to “see” the surroundings. Besides these gadgets, smart healthcare products have moved towards personalized health monitoring as well. Technology enabled application that detect the number of steps one takes, calories burnt, sleep quality, heart rate and distance walked/ran is recorded and based on a personal score provided by the application helps the patients or consumers to determine healthy life.

Globally, doctors have been benefitted with an increase in use of Smart Healthcare Product. Apps that allow patients’ reports of electrocardiograms are being sent over email, which saves a lot of time and work at doctor’s end. Adding and collecting of data to a patient’s profile, assessing data anytime owing to the availability in cloud into a centralized ledger will make diagnosis and treatment procedure much simpler. Patients have been more willing to share their data with healthcare companies as the process seems far simpler than the traditional process followed by healthcare companies. Thus doctors, patients and health enthusiast globally will drive the growth of Smart Healthcare Products’ market.

The Smart Healthcare Product market has been segmented majorly into product type and industry vertical. Product type segment is further bifurcated into smart pills, smart syringes, smart RFID cabinets, and Electronic Health Record. The industry vertical deploying the smart healthcare products include monitoring and treatment, health data storage and exchange, and inventory management.

Smart healthcare has emerged to be one of the most innovative, dynamic, impactful and exciting area with lots of opportunities for growth. The impact of growth of smart healthcare products has been positive and has consequently generated a demand at consumers’ end. This is a positive shift in the market of smart healthcare products and has propelled companies operating in this field to meet the demand. Leading companies in this field are Epic Systems Corporation, Medtronic, Becton Dickinson & Company, Stanley Healthcare, Allscripts Healthcare Solutions Inc., Olympus Corporation, and Terumo Corporation. With Internet of things being the driving force behind this product, this market is set to witness a substantial growth in the next decade.


The Internet of Things (IoT) Healthcare market was valued at USD 28.42 Billion in 2015, and is projected to reach USD 337.41 billion by 2025, growing at a CAGR of 28.2% over the forecast period. Rising investments in healthcare IoT solutions, implementation of IoT solutions for cost reduction, and the growing penetration level of connected devices in the healthcare industry are few factors projected to spur the IoT healthcare industry. 

Growing awareness for advancement in AI technology and disease management tools such as remote patient monitoring, telemedicine, and Health Management Information Systems (HMIS) is also anticipated to gain traction globally. For instance, as per Healthcare Intelligence Network (HIN) report in 2014, over 30% of the U.S. population with chronic disorders focuses on homebound treatment with remote monitoring programs.

Healthcare sector has started focusing on implementing IoT & AI technology to improve patient care by various technologies including interoperability of medical devices, digital patient experience, and scalable therapeutics. UroSense App by Future Path Medical for catheterized patients to check their body temperature and urine output, Niox Mino App by Aerocrine for routine measurements of Intric Oxide in a patient's breath are few apps launched by healthcare sector implementing IoT technology. Additionally, OpenAPS (Open Artificial Pancreas System) for closed loop insulin delivery, Continuous Glucose Monitoring (CGM) system, connected inhalers, and ingestible sensors are few advanced IoT technologies implemented in healthcare industry. 

Nanobots & robotic flight stimulator surgeries, increasing demand for effective treatment, big data analytics in healthcare, and increasing awareness for upgraded technologies among patients are some of the trends shifting the global healthcare industry towards IoT applications. Moreover, increasing demand for low-cost disease management & treatment, accuracy of sensors, lack of exposure in emerging regions, and rising prevalence of chronic diseases are creating opportunities for the IoT healthcare market over the forecast period. Although, rising concerns about patient privacy and security breaches might affect the global market over the forecast period.

On the basis of component, the report displays the revenue, market share and growth rate of each type, primarily split into:

•    Medical Devices  
•    System & Software 
•    Services 

On the basis of application, the report displays the revenue, market share and growth rate of each type, primarily split into:

•    Telemedicine 
•    Medication Management
•    Clinical Operations
•    Inpatient Monitoring
•    Connected Imaging
•    Others

On the basis of end-user, the report displays the revenue, market share and growth rate of each type, primarily split into:

•    Hospitals, Surgical Centers, and Clinics
•    Clinical Research Organization (CRO)
•    Government and Defense Institutions
•    Research and Diagnostics Laboratories

Remote device management is anticipated to hold the largest revenue share in software and systems segment owing to rising awareness regarding tele-health technology, increasing demand for technologically advanced remote patient care programs, and growing prevalence chronic diseases.

Hospitals and clinics have been anticipated to acquire the largest share over the forecast period. Increasing efficiency, growing focus on better patient care and reducing treatment cost, are few factors contributing to the industry growth. Furthermore, growing awareness regarding the benefits of IoT implementation in healthcare centers is also a substantial factor for the largest market share.

Adoption of IoT in research and diagnostic centers enable reduction in diagnostic cost, improvement in patient care, and reduction of machine downtime accelerating the usage of connected equipment. Inpatient monitoring has been projected to emerge as the largest application segments owing to rising demand for continuous patient care services, real-time disease management, and effective treatment outcomes.

Geographically, the global market report has been split into North America, Europe, Asia Pacific, the Middle East and Africa and Latin America, with revenue (Billion USD), market share and growth rate of IoT Healthcare market for these regions, from 2015 to 2025 (forecast),

•    North America: U.S., Rest of North America
•    Europe: Germany, France, UK, rest of Europe
•    Asia Pacific: China, Japan, India and Rest of Asia Pacific
•    Middle East & Africa: GCC, North Africa, South Africa and Rest of MEA
•    Latin America: Brazil and Rest of Latin America

North America is estimated to dominate IoT healthcare market owing to few major contributing factors including data protection of EHR & IPR regulations and sophisticated healthcare IT infrastructure. Moreover, local presence of key players such as Microsoft & IBM, continuous R&D initiatives by the key players, and faster implementation of IoT in healthcare centers are also projected to boost the usage rate. Asia Pacific region is predicted to emerge as fastest growing region over the forecast period. Growing government initiatives for healthcare providers & other organizations to implement EHR & EMR technology is one of the major factors foreseen to boost the market. 

Overview of market leaders in IoT Healthcare market by top manufacturers/players, with IoT Healthcare revenue (Billion USD) and market share for each manufacturer/player; the top players including Medtronic Inc., Koninklijke Philips N.V., General Electric Company, International Business Machine (IBM) Corporation, Microsoft Corporation, Cerner Corporation, Proteus Digital Health Inc., AdhereTech Inc., Google, and Cisco Systems.

R&D activities, new advanced product launches, mergers & acquisitions, and expansions are few strategies adopted by industry players to cater to the needs of the industry. For instance, in 2015, the International Business Machine Corporation (IBM) collaborated with Medtronic PLC to provide IoT services for Medtronics medical devices data. A major chip manufacturer Qualcomm Life Inc. has acquired medical device data integration provider Capsule Technologie in 2014.


Umbilical cord is the connecting cord from fetus to the placenta which allows blood to carry nutrition and oxygen to the baby in the womb. Umbilical cord blood banking (UCB) or cord blood banking involves in collection of cord blood and extracting and cryogenically freezing the stem cells of the immune system for future medical purpose. The tissues of umbilical cords contain Haemopoitetic Stem Cell (HSC) which have greater proliferative and colony forming capacity. HSC collected from tissues works as an alternative for HSC of bone marrow providing treatment of various immune diseases such as myelomas, leukemias, lymphomas and myeloproliferative neoplasms, and blood disorders.

Umbilical cord blood is considered to be the safest decision owing to the non-invasiveness and least risk to the child and mother. Additionally, UCB is expected to be a probable source of progenitor cells, which are used for reconstitution of organs and tissues. With naïve technologies, UCB are used for treatment of various diseases such as bronchopulmonary dysplasia, diabetes mellitus, malignant solid tumors, hepatic alteration, cardiovascular disorders, neurological diseases, inborn metabolic disorders, and hematologic malignancies.

Various applications for chronic diseases treatment, cost effective therapy, and easy extraction methods for cord blood is expected to drive the industry demand. Furthermore, intact genetic structures, lower incidence & severity of graft, and lower incidence of viral transmission is also impacting the market growth industry positively. Moreover, rising awareness regarding the benefits, varied availability of donors along with insurance coverage are few of the factors thrusting the demand for UCB market globally.

Additionally, increasing disposable incomes and appropriate payment plans accessed by the market players are also fueling the growth for cord blood banking services. Although, high cost for storage, lack of donors, least count of HSC in each donation, collection and risk of non-usability of the unit stored with private bank are the major factors hindering the growth of the market.

The global umbilical cord blood market is segmented into storage type, end-user, and application. On the basis of storage, the market is segmented into public banks, private banks and hybrid banks. Private Banks offers UCB storage for personal use of the donor’s family with storage charges. Despite of hefty charges, private banks are the first choice of parents to store cord blood owing to various factors such as flexible collection sites, secured access, and complete ownership rights. The end-usermarket is segmented as hospitals, pharmaceutical research, and research institutes. The application segment covers treatment of various disorders such as cancers, blood disorders, metabolic disorder, and osteopetrosis.

North America region is anticipated to dominate the UCB market owing to extensive presence of private companies creating huge public awareness. Europe region also accounts after North America market owing to the high healthcare expenditure and rising awareness programs. Though, government restrictions for private banks establishment in some of the regions such as Italy & France are decelerating the growth of Europe market.

Asia Pacific regional market is estimated to grow over the forecast period owing to awareness in emerging countries such as India, China, Hong Kong and, Japan. Booming healthcare sector and accelerating investment by international companies to take advantage on the geographical spread are some of the factors estimated to stimulate the market in the region. Furthermore, growing medical tourism is also expected to fuel the demand for UCB services in the region.

Cord blood banking market is witnessed as the most distinguished and competitive market involving large number of players such as Cordlife Group Limited, Cryo-Save AG, China Cord Blood Corporation, National Cord Blood Program, Cord Blood America, Inc., Lifeforce Cryobanks, CBR Systems, Inc., Cryo-Cell International Inc and Virgin Health Bank.


Women and men share various similar health problems, but women have their own health issues which needs special attention. Women’s lives have changed over century and was more difficult. Most women did not live long enough due to their numerous dangers and diseases. Women's health differs from that of men in several distinctive ways, owing to various social, biological, and behavioral circumstances. Women's health refers to their reproductive health, such as maternal health, sexual health, infertility, child marriage, menstrual cycle and other issues, and non-reproductive health such as cardiovascular disease, cancer, mental health, anemia & violence. Women’s health is broadly affected by various socio-cultural factors such as employment, poverty, and family responsibilities and biological factors.

Global efforts for women health improvement in the past, have majorly focused on decreasing unsatisfactorily level of morbidity and maternal mortality. These efforts have brought a rapid decline in women’s diseases leading to the foremost causes of women’s disability & deaths in almost all countries are now non-communicable diseases.

Although, there are various similarities in the women health issues around the world but few striking differences are majorly due to the varied conditions in high and low income countries. Women health in these countries is critically affected by various socio-economic factors, such as access to education, household wealth and place of residences.

Growing female geriatric population, favorable government policies,  various initiatives by private organizations with the introduction of new medicines for women and unhealthy lifestyles of women are few of the factors responsible for market growth. Additionally, escalation in public-private funding and endowments for infertility treatment due to high costs associated, are projected to spur the global women health market.

As per International Osteoporosis Foundation (IOF), worldwide prevalence of osteoporosis amongst women was over 200.0 million in 1990, and has been projected to reach 680.0 million by 2050. Moreover, women are more prone to certain diseases such as osteoarthritis, depression, anemia, osteoporosis, obesity menstruation-related disorders. Henceforth, rising incidence for these disorders are likely to enhance the market over the forecast period.

Women’s health market is categorized based on of treatment type, diseases indication, and distribution channels. On the basis of treatment type, the market is segmented as non-hormonal and hormonal. Diseases indication segment is divided as Urinary Tract Infection, hypothyroidism, Uterine Fibroid, osteoporosis, Cancer, contraceptives, Post-Menopausal Syndrome, and others. Other diseases indication includes anemia, mental health, and violence. By end-users, the women health industry has been segmented as hospitals and clinics, diagnostics and imaging centers, and home care..

Contraceptives are anticipated to be emerging segment over the forecast period owing to rising consumer awareness for family planning and technically progressive contraceptive methods. Moreover, encouraging government regulations in nations such as the U.S., coupled with rising cognizance about various contraceptive methods, are likely to spur the contraceptive applications, and is predicted to improve the segment growth.

North America region is expected to hold the major share in the women’s health market. Rising inhabitants of older women in the region is one of the significant factor boosting the market growth. Furthermore, increasing awareness, healthcare expenditure, and rise usage biologics preference in women are some of the other significant factors accredited to the dominance of the region.

Asia Pacific region is estimated to witness significant growth owing to a huge population and swelling demand for contraceptives. Rising government initiatives in India, Sri Lanka, Bangladesh and China for population control are likely to impact positively on the women’s health market.

Several prominent players in the women’s health market are Allergan, Agile Therapeutics, Amgen, Inc., AstraZeneca, Bristol-Myers Squibb Company, Bayer AG,  Merck & Co., Inc., Ferring B.V., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. These companies are engaged in R&D collaboration, product portfolios expansion, and regional development in order to increase their market share. Also, investments made by players for new product entries will spur the global market.


The global cell culture market was valued at USD 11,210.7 million in 2015 with a CAGR of over 10% over the forecast period. Increasing R&D activities of healthcare, biological, and stem cell applications has enhanced the demand of molecular biological activities which is further projected to persist a vibrant aspect for market growth. . The introduction of advanced technologies such as rDNA technique, proteomic & genomic shaping, and genetic engineering has made the cell culture technology as an indispensable tool.

Increasing cases of chronic diseases has led to the firm growth of cell culture technology applications in drug discovery, cancer diagnosis and biologics production. Rising growth in the number of regulatory approvals for cell culture-based vaccines and increasing funding for cell-based research will also influenced the market positively. Furthermore, growing application of single-use technologies and rising demand for mAbs are few factor projected to spur the market growth. . Additionally, affluence from various applications such as genetic engineering, research model systems, and continuous research related to cellular functions and stem cell research is also expected to drive the cell culture process globally.

Cell culture technology includes several complications including raw material supply and fully traceable botanical extracts. Also, growing attention on certifying regulatory compliances associated with environmental sustainability can impede the efficacy of the technology. To overcome these complications, in 2017, researchers from News Medical Life-sciences swayed towards culture model development which can be used for initial treatment of Age-Related Macular Degeneration (AMD) which is considered to be the major cause for vision loss and is more prevalent in elderly people.

The cell culture technology application has enhanced to the extent where the orthodox manual small scale production and cultures handling is not enough to surpass the demand for new age production. . This has led to the growth of computerized large-scale cell culture processes capable of fabricating high throughput cell cultures in larger quantities with excellent purity.

Few other factors spurring the growth includes rise in life sciences research, cell based technology advancement, cumulative cell based production, and mounting demand of cell based therapies. Though, extensive cost involvement in cell culture research, lack of awareness for diagnosis technologies, and high contamination risks may hinder the market growth. Furthermore, optimization & handling of cell-based protocol in vitro studies will defies the market growth.

Broadly, the market has been segmented on the basis of products and application. The product segment is further bifurcated into consumables and instrument segment. Consumables segment includes media, reagents, and sera, while instrument segment includes incubators, pipetting instruments, culture systems, centrifuges, cryostorage equipment and biosafety equipment. Based on application segment, cell culture technology has various applications in cancer research, drug development, biopharmaceuticals, vaccine production, tissue culture & engineering, gene therapy, and toxicity testing.

Culture Systems segment holds the significant share in 2015

Cell culture media segment is expected to have brisk development owing to growing trend for Animal Derived Component Free (ADCF) media. Technical innovations in functionality & designs of cell culture devices and firm recognition for mechanized culture methods by various prominent players are key aspects encouraging the growth of instruments segment.

Culture systems segment is projected to contribute majorly as the devices in the segment have fundamental impact to any cell culture technology. Culture systems include culture plates, T-flasks, culture bags, bioreactors, roller bottles, and centrifuges. Furthermore, spheroid development and complex bioreactors advancement has provided several opportunities for introducing 3-D cell cultures contrasting to the traditional 2-D cell cultures.

Biopharmaceuticals segment is expected to generate major revenue in the application segment followed by vaccines production owing to mass culture of animal cells, particularly mammalian for viral vaccines and biotechnological products.

North America holds largest share in overall market

North America dominates the global cell culture market share owing to the instant development of automated cell culture processes, and rise in stem cell therapy application. Cell culture technology has major application in Canadian & U.S. life science laboratories majorly for cellular expression, cultivating monoclonal antibodies, pluripotent stem cell research and cryobanking responsible for more than one third revenue generation.

In Asia Pacific region, particularly in Japan, automatic single cell examination and segregation systems for advanced stem cell therapies are also projected to spur the cell culture market over the forecast period. Furthermore, increasing investments in pharmaceutical and healthcare sector and growing support from non-government and government bodies is also anticipated to boost the industry growth.

Prominent participants of the cell culture technology include Sartorius, Thermo Fisher Scientific, Merck, Corning, Sigma-Aldrich Co., LLC, Promocell, General Electric, Eppendorf and Becton, Lonza, and Dickinson & Company. The industry players are majorly focused in the development of 3D cell culture methods that are considered to be the improved version of two dimensional cell cultured methods which is further expected to propel the development and growth of the industry globally.


The implementation of mixed reality (MR) technologies in healthcare industry has enhanced the operational environment. Mixed reality technologies are Augmented Reality (AR) covering moving and static images to boost an actual environment and Virtual Reality (VR) which engages the observer in a simulated 3D environment. The amalgamation of IT solutions in healthcare field has brought transformational change in the perspective of patients’ treatment and services offered by healthcare specialists. The benefits associated with digitally managed operations & processes are encouraging naive companies in the healthcare industry to transform them to more proficient software-enabled solutions from using conventional operated devices.

AR & VR technologies have transformed the healthcare sector with their implementation in virtual training of medical practitioner for challenging surgeries, phobia buster in mental health treatment, 3D operating room simulations, and chronic pain management. For instance, VR technology has played a substantial role in Eye Movement Desensitization and Reprocessing (EMDR) therapy which empowers to overcome traumatic memories via particular eye movements. Furthermore, these technologies also benefits in various areas of care management such as autism & depression therapy, cancer therapy. VR-based organ prototypes have played a fundamental part in preparing medical practitioner for complicated & delicate operations which requires reduced trauma, less complications with greater precision.

The growing implementation of digitalization & technology in healthcare sector, focus on delivering efficient services, significance in training professionals, rising healthcare expenditure, and offering innovatory solutions for real-time care services are few of the factors anticipated to enhance the market growth in the forecast period. Furthermore, protective medicines application, medicinal visualization, surgical computers, are various health apps contributing to the growth of dispersion of AR & VR technologies in Healthcare sector.

Growing awareness among people towards MR is one of the major factor driving the patient-care management application in healthcare market. Various naïve technologies such as AR and VR would assist the patients to remotely avail the doctor's consultation. Although, high costs involvement in VR software and supporting hardware devices might alter the growth, otherwise the market has exceptional growth prospects, especially in emerging countries. However, substantial funds brought in the field of medical education, especially in emerging countries such as India and China, are anticipated to fuel the implementation of MR in medical education field, associated with the VR & AR growth in healthcare sector.

The global market has been segmented by offerings, device types, end-users, and application. On the basis of offerings, the sector is further segmented as hardware components and software components. Hardware components are further bifurcated as sensors, semiconductor component, display & projectors, position trackers, and cameras, while software components are segmented as software development kits and cloud-based services. Based on device type, the global MR surgical industry is categorized into AR devices which further include AR Head-Mounted Display (HMD) and handheld display; and VR devices including VR Head-Mounted Display (HMD), gesture-tracking device; projectors and display walls. The end users for the global market are Hospitals, Clinics & Surgical Centers, Research Organizations & Pharmaceutical Companies, Government & Defense Institutions, and Medical Training and Education. Application segment is bifurcated as surgery, fitness management, Patient Care Management, Pharmacy Management, and Medical Training and Education.

North America is expected to contribute majorly in the market share, which can be credited to continuous technological advancement, pervasiveness of neurological & psychological disorders, and presence of a urbane healthcare infrastructure. Moreover, rising technological advancements in information technology, government support and rigorous R&D activities in the region along with the presence of numerous market players are also contributing to the huge share of the region.

Major players dominating the industry include Atheer, Augmedix, Daqri, Echopixel, Firsthand Technology, Medical Realities, Microsoft, Mindmaze, Oculus VR, Orca Health, Osso VR, Osterhout Design Group, Psious, Samsung Electronics, Start-Up Ecosystem, Surgical Theatre, and Widerun. . Huge funding for R&D coupled with new product launches and various corporate strategies such as mergers and acquisitions are the vital strategies deployed by the prominent players to capture a larger share and maintain the dominance in the global market.


Mice model has become one of the essential model for dealing with human pathophysiology and disease progression owing to remarkable resemblances between the genetics, anatomy, and physiology mice and humans. These similarities promote mechanisms of different diseases, understanding of the functions of individual genes, scientific discovery, and the effectiveness and toxicities of various drug molecules.

The mouse is the only mammal which offers a rich source for extensive genome manipulation coupled with the potential of genetic diversity, hence evolving as a significant application for modeling human disease. Mouse model shares several features similar with human brain functions such as circadian rhythm, hunger, memory, anxiety, and other emotional responses. New prototypes are technologically advanced where the human tissues and cells are being reconstructed.

Mice Models are widely popular among other animal model owing to their short generation time, small size, low cost, accelerated lifespan, and requirement of less space. One mouse year equals about 30 human years. The genes responsible for operating and building both organs are 90% similar which can help in understanding the mystery of human mental disorders, intelligence and memory related phenomena.

The global market is expected to grow along with the increase in genetic market. Rising demand for personalized medicines and steady increase in R&D of pharmaceutical sectors regarding mice model will positively impact the market. Furthermore, these markets have wider application in the research practices of the various rare diseases, hence aggregating the global demand of the market. rise in monoclonal antibody production has also contributed in the model growth.

Venture capitalists, Clinical Research Organizations (CROs), government and private institutes, medical research centers, mice model & service companies and distributors, animal care products manufacturer, IN &OUT licensing sciences companies (mainly Pharmaceutical, Biotechnology & Biopharmaceuticals), animal healthcare associations, and academic institutes are few consumers producing huge scope for the industry growth over the forecast period. Popularity of humanized mice models, ongoing advancement in mice models and continuous support in terms of investments from the consumers results in market growth.

The global market is categorized as types, services, applications, and technology.The mice model market based on type, is segregated into conditioned/surgically modified mice, genetically engineered mice, outbred mice, spontaneous mutant mice, hybrid/congenic mice, and inbred mice. On the basis of technology, the industry is bifurcated as nuclear transfer, microinjection, CRISPR and embryonic stem cell injection, and others. Other technologies include TALENs & ZFN, DNA electroporation & liposome-mediated DNA, biolistic, virus or vector-mediated gene transfer are also different technology practiced in mice model market.

The industry application includes cardiovascular studies, oncology studies, rare diseases, immunology and inflammation studies, toxicology, diabetes studies, central nervous system studies, hematopoiesis, renal disorders, and others. Based on services, the market is sub-divided into quarantine, surgical, rederivation, line rescue, genetic testing, and others such as breeding, model in-licensing, cryopreservation, and in vivo pharmacology services. Oncology application market is expected to acquire the major share of the industry whereas breeding services from service segment is also expected to contribute majorly to the mice model market.

Geographically, North America region is anticipated to hold the largest share, followed by Asia-Pacific and then Europe. Although, APAC region market is anticipated to grow substantially over the forecast period owing to their well-established pharmaceutical sector and sophisticated biosciences research.Majority of the mice models and transgenic business has been covered by Asia Pacific region particularly in Malaysia, Singapore, China, and India.

The Jackson Laboratory, Charles River Laboratories International Inc., Envigo., Taconic Biosciences, Inc., Laboratory Corporation of America Holdings, Harbour BioMed (China), TRANS GENIC, Inc., JANVIER LABS, genOway, Horizon Discovery Group plc, and JANVIER LABS, are some of the key players in the market. A qualitative analysis of these key players operating globally for mice model market is anticipated to help vendors to generate informed decisions along with being attentive in their industrial operations.


Internet of Medical Things (IoMT) allows machine to machine interaction and provides real time intervention solutions which further assists in transforming the healthcare affordability, delivery, and reliability over the forecast period. The advancement of artificial intelligence along with growth in IoT in healthcare solutions and investments is expected to drive the market. With IT services platforms and advancing technologies, healthcare industry is more exposed for bringing radical changes in the market.

Increasing geriatric population along with technological advancements are few factors spurring the market over the forecast period. Also, awareness for advance disease management tools such as remote patient monitoring, Health Management Information Systems (HMIS) and telemedicine are also other probable factors propelling the market.

Tracking devices and wearable devices are also entwined with evolving healthcare models. Moreover, technological innovations in smartphones including Advanced RISC Machine (ARM) cortex M processor, and increasing demand of first-generation IoT medical devices, such as fitness bands & smart watches are few driving factors representing the penetration of technologies in global industry.

Few other key factors boosting the growth includes rapid adoption of new technologies in healthcare industry such as data analysis, data management, and data transfer through machine to machine (M2M) communication services wearable user interface, and, hybrid cloud computing.Furthermore, upgraded technological advancements such as nanobots & robotic flight stimulator for surgeries, big data analytics, rising demand for effective treatment, are few substantial factors positively influencing the market growth. Emerging demand of home healthcare services, increasing costs of hospital equipment, and increasing pediatric and geriatric populations will also enhance the growth over forecast period.

Apart from advantages of cost savings, profitability, and customer experience, Internet of Medical Things (IoMT) also assists in financial interests for stakeholders including physicians, investors, providers, and investors. These advantages helped to transform the traditional healthcare industry into proactive care-deliver centers.

The rise of IoMT has addressed the imminent need for targeted therapeutic tools along with better diagnostics. Furthermore, apart from working as remote patient monitoring for physicians, the technology also performs the tasks as a dose reminder for patients along with wellness and fitness tracker for athletes. Effective application of IoMT in remote observant for asthma and diabetes patients with mutual penetration of wellness and fitness devices have created a huge demand in the market.

The global market has been segmented by components, by application and by end-users. The components segment is further bifurcated as devices, systems and software, and services. The market has varied application from telemedicine, medication management, patient monitoring, connected imaging, drug development to fitness & wellness measurement.  The end-users for the market  include healthcare providers & payers, patients, government authorities and biotech research labs.

North America region is projected to dominate the IoMT industry owing to various factors such as Electronic Health Record (EHR) & Intellectual Property Rights (IPR) regulations as well as established healthcare IT infrastructure. The technological initiatives from IBM and Microsoft  for IoMT have led the U.S. to lead the North America region. Asia Pacific region is been anticipated to grow steadily owing to the initiatives taken by government to adopt EMR and EHR technology.  The involvement of private sectors and nonprofit entities for information exchange, better clinical outcomes and cost effective approaches is also anticipated to spur the market over the forecast period in the region

Key market players for IoMT include CISCO Systems, Microsoft Corporation, IBM, and CERNER. Other notable players are Proteus Digital Health,  GE Healthcare Ltd., St. Jude Medical Inc., Google (Alphabet), Qualcomm Life Inc., Medtronic PLC, International Business Machines Corporation, and Koninklijke Philips N.V.


Medical waste management is referred as the process of regulating the generation, treatment and disposal of medical waste by the healthcare institutions. These medical wastes are generated at health care facilities such as blood banks, physician’s office, clinics, veterinary clinics/hospitals as well as medical research facilities and laboratories. The emergence of the medical waste management techniques has played a major role in preventing the discharge of toxic compounds into land and water.

Improper management of medical waste in the facilities causes a direct impact on the environment, on the community’s health and healthcare workers. Increasing initiatives for improving the medical waste management services by regulatory authority and the generation of huge amount of medical waste is expected to spur the market growth over the forecast period.

Increasing geriatric population, rising prevalence of chronic disorders and diseases such as cancer is projected to fuel such advancement in the medical solutions. The development of innovative techniques for development of drugs and medical devices in the medicinal industry is growing at enormous rate.

Furthermore, the efficient supply of inventories required in function of the clinics, hospitals leading to the generation of the massive medical waste which is further demanding for the proper system for collection, disposal, transportation and recycling of materials. The development and implementation of the advanced techniques for treatment and disposal of these waste is anticipated to further enhance the industry demand.

The outsourcing of these medical waste treatment services has further unlocked an array of growth opportunities for industry. However, lack of training for proper disposal, lack of awareness about health hazards associated with waste and high initial capital investment is also expected to restraint the market.

The market for the medical waste management is segmented on the based on the type of waste, service, treatment, disposable site and regions. The types of waste generated are hazardous and non-hazardous and the services offered in the industry include treatment, disposal and recycling. On the other hand, these wastes can be treated by chemical treatment, incineration, autoclaving and others. Furthermore, the treatment sites included for the medical waste are onsite and offsite. On the basis of geography, the market is segregated into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

North America is expected to the major share in terms of revenue in the market owing to the growing healthcare industry. Furthermore, Asia Pacific region is projected to witness enormous growth over the forecast period owing to rising social awareness and government initiatives for proper disposal of byproducts and residues.

The key players in the market include Clean Harbors, Inc., BioMedical Waste Solutions, REMONDIS Medison GmbH, Sharps Compliance, Inc. Daniels Sharpsmart, Inc., Republic Services, Inc., Suez Environnement S.A., Stericycle, Inc., Waste Management, Inc., and Veolia Environnement S.A. These companies hold the major share in the market and are expected to adopt various strategies to maintain their position. Furthermore, the companies are also collaborating to favor the new innovative techniques for disposing the waste.


The global healthcare market size was estimated USD 3.76 Billion in 2014 and is expected to witness significant growth over the forecast period. Healthcare robots are used in wide range of applications which include drug manufacturing, dispensing drugs to patients and moving inventory in medical supply facilities.

Increasing demand of the surgical robots such as da Vinci surgical systems is expected to intensify the market growth over the forecast period. These robots offers 3D HD vision systems for a magnified and clear view of patients body and assist doctors in various complex procedures with high precision and flexibility.

The healthcare centers are investing heavily on the robotics industry for minimizing the cost which include high cost manual label of operation and for greater flexibility of functioning of the healthcare. Majorly the healthcare centers are investing in automatic guided vehicles (AGVs) for transporting patient needs such as delivering meals, linens, nursing supplies, packages, sterile items, oxygen and gases, and pick-up trash.

Increasing government subsidies for installing and implementing the healthcare robots in the countries such as China and India has further led to enhance the market growth. Another factor enhancing the industry growth is the workforce shortage in the sector. According to World Health Organization (WHO) report, 83 countries fall below the threshold of 22.8 skilled healthcare professionals per 10,000 population and 100 countries fall below the threshold of 34.5 skilled healthcare professionals per 10,000 population.

The market is segregated into two major segments which include rehabilitation robots and robotics surgery market. The rehabilitation robotics consists of prosthetic robotics, exoskeleton robotic system, orthotic robotics, and therapeutic robotics. The robotics surgery market is further segregated based on the components and services which include robotic surgical systems, instruments and accessories, and services.

The robotic surgery holds the major share in the market owing to wide scale improvements in patient monitoring, and the ability to deliver better medical results with high accuracy and precision while implantation and component replacement in orthopedics is expected to enhance the market growth over the forecast period. The application of the robotics surgery includes gynecology, urology, and general surgery.

Although, the high cost associated with healthcare robots induce the patients to go for normal treatment. However, emerging trends which include implementation of robotic in-patient rehabilitation programs and replacement of manual surgical assistance indicate the immense growth over the forecast period.

North America market is projected to dominate the market owing to increasing government spending in the healthcare infrastructure sector. U.S. is investing heavily in healthcare sector since the aging population has increased densely in metropolitan cities. According to the American Society of Aesthetic Plastic Surgery report in 2014, a total of 1,764,956 procedures have been carried out in cosmetic procedures.

The industry in APAC region is projected to grow enormously as the countries such as China, South Korea and India has been adopting healthcare robots in rehabilitation centers and hospitals. Furthermore, Japan is expected to lead the healthcare robotics industry owing to increase need for reduced lead time for addressing the patients and for aging population.

The key vendors dominating the market include Elekta, Mazor Robotics, Intuitive Surgical, Tecan Group, Qiagen, and Varian Medical System. Other companies include Titan Medicals, Curexo Technology, THINK Surgical, Hansen Medical, and Health Robotics.


Stem cells are the undifferentiated biological cells which has the ability to differentiate from other specialized cells. These cells are also referred as the building blocks of life as they have the ability to self-renew after splitting into two cells. Furthermore, these cells have the potential to remain either the same or can adapt to different types such as a brain cell, blood cell or a lung cell. These cells can be developed to become organ-specific or tissues-specific which can be used to replace the damaged tissues in the bone marrow or gut.

Increasing research for broadening the utility scope of these cells has expected to drive the market growth. The ongoing research on these cells has provided the opportunity of implementation of these cells for clinical applications, thereby influencing the treatment.

Increasing developments in the new technologies for storing the stem cells and growing awareness among the parents for stem cells in developed and developing countries have led to fuel the market demand. Enormously growing the field of regenerative medicine based on the stem cells and increasing application of these cells for therapeutics has further influence the growth of the market in a positive manner.  

The stem cells market can be segmented based on the product which includes adult stem cells, human embryonic stem cells, induced pluripotent stem cells, very small embryonic like (VSEL) stem cells.  Adult stem cells can be extracted from various areas of the body which include fat, bone marrow, and peripheral blood. Adult stem cells are expected to have the major market share owing to low contamination probability while sub-culturing and less production labor. Furthermore, the capability of induced pluripotent stem cells of unlimited self-renewal and reproduction when cultured is anticipated to increase the demand over the forecast period.

The major application of stem cells is regenerative medicine which is expected to hold the potential share in the market for curing traumatic injury and degenerative disease. Furthermore, the pharmaceuticals companies have unleashed the new opportunities based on the stem cells by enabling firms to develop novel drugs. Increasing reliability on cellular systems for drug development is projected to influence the market share over the forecast period.

 Increasing R&D projects in Asian countries which include Australia, Japan and Singapore owing to accelerated commercialization opportunities in the region is expected to fuel the market growth. Furthermore, the regulatory changes with respect to regenerative medicine in Japan have attracted substantial interest in the market. North America region is also projected to hold the major share in the overall market owing the availability of federal funding for the stem cell research.

The key players in the market include StemCyte, CBR Systems, ViaCord, Cryo-Cell International, LifeCell International, Celgene Corporation, Smart Cells International, Cordlife Group and Chine Cord Blood Corporation. The market has been witnessing the rise in the mergers and acquisitions for diversifying and strengthening their presence in the market and for occupying the major share through alliances with smaller players across the globe over the past five years. For instance, the AMR Pharmaceuticals acquired cord blood registry (CBR) in March 2015 and the acquisition of Insception Lifebank (based in Canada) by Cell Care from Australia in October 2016.


Patient Portal Softwareis access point that are used for secure patients access to data related to patients’ personal care and well being. In addition, this system are used to communicate with healthcare professionals and scheduling appointments. Some of the features that can be accessed are results of lab tests, patient education materials, discharge summaries, downloadable forms, recent doctors visit, payment process, prescription refill ordering, immunization records etc. It provides a holistic view of the patient’s history and a means of easy communication with the doctors and other members in the ecosystems. With the implementation of patient portal software any organization can leverage the communication between the service provider and the patients and improve patient’s outcomes. With the growing demand for electronic health records across medical organizations, both private and public, would lead to increase in the demand for the patient portal platforms for an efficient and seamless productivity.

 Growing adoption of electronic health records solutions and patient-centric approach by healthcare payers and providers, popularity of patient portals among elderly populationsare some of the factors that would drive the growth of global Patient Portal Software Market. Data security and privacy concerns, high cost of initial deployment and integration of the system onto the legacy infrastructure are expected to hinder the growth of the Patient Portal Software Market to the certain extent.

The global Patient Portal Software Market can be segmented on the basis of type, deployment type, application and region. On the basis of type, the global Patient Portal Software Market can be segmented into software and services.The service segment can be further broken down into consulting, integration, managed and maintenance and support services. On the basis of deployment type, the global Patient Portal Software Market can be segmented into on-premise and cloud-based. On the basis of application, the global Patient Portal Software Market can be segmented into home care, healthcare providers, hospitals, payers and others. On the basis of region, the global Patient Portal Software Market can be segmented into North America, Europe, Middle East & Africa, Asia-Pacific, and Latin America. In addition, North America and Europe Patient Portal Software Market accounts for a larger share in the global market. In addition, Asia-pacific Patient Portal Software market is anticipated to grow at a high CAGR during the forecast period.

Some of the key players in the global Patient Portal Software Market include Allscripts Healthcare Solutions, Inc., Mckesson Corporation, Athenahealth, Cerner Corporation, Eclinicalworks, Curemd, Nextgen Healthcare Information Systems,LLC (Subsidiary of Quality Systems, Inc.), Greenway Health, LLC, Medfusion, Inc. and Epic Corporation, Inc.


The smart pills technology is the grouping of the technology and healthcare focusing on the medication copy based on various factors such as pressure pH, density, temperature, etc. Diseases pertaining to gastrointestinal tracks such as gastroparesis, hemorrhoids, gastroesophageal reflux diseases (GERD), colitis, constipation, gastric ulcers,  and diarrhea are expected to provide this market with a growth platform. Furthermore, technological advancements comprising of software-based wireless capsules, analysis, enteroscopy, esophageal stenting, and few and esophageal banding clubbed with growing demand for negligibly invasive surgical procedures are also anticipated to propel the growth of smart pills market.

The global Smart Pills market has be categorized into target area, application and regions. Based on the target area the market has been segmented into esophagus, stomach, small intestine and large intestine. Applications segment has be categorized into drug delivery, capsule endoscopy, and patient monitoring.

The major factors driving the smart pills market are rise in the increased patient preference for minimal invasive surgeries, technological advancements in capsule endoscopes, favorable reimbursement coverage in selected countries, growing incidences of colonel cancer, entended indication coverage for the use of capsule endoscopes in Japan, bowel scope screening in anticipated to have a positive impact on the endoscopy market majorly in U.K, aging population in  Europe region, reimbursement approval of diagnostic and screening capsule endoscopes for colon in Japan, and the endoscopy training workshop and huge investment done by the government of Australia. Rising sophistication in smart pills to increase prices and technological incompetence of capsule endoscopes are major factors that may hinder the progress of the Smart Pills market in the near future. Additionally the growing opportunities for the cross-domain collaborations, emerging smart cities and government funding in research and development and innovation related to IoT are some of the major growth opportunities for the Smart Pills market players.

Geographically, the smart pills market has been bifurcated into five regions North America, Europe, Asia Pacific, Middle East & Africa and Latin America. The smart pills market size and forecast period for each region has been estimated from 2017 to 2023. Additionally the CAGR (%) for the forecasted period 2017 to 2023. The study also includes market estimates for major countries/regions such as the U.S, the U.K., Germany, France, Japan, China, India, GCC, North Africa, South Africa and Brazil. The detailed analysis by target area, application, and regions supports in evaluating the present scenario, growth prospects and the future scenario for the Smart Pills market over the forecast period. Thus, the report delivers in-depth segment analysis of the market and classifies it into various industries, thereby providing valuable perceptions.

The growing aging population is anticipated to drive the Europe market for Smart Pills in the future years. The major companies that are involved in Smart Pills are GE Healthcare, Given Imaging, Inc., Cerner Corporation, Proteus Digital Health, Inc., Karl Storz GmbH & Co. KG, Fujifilm Holdings Corporation, Olympus Corporation, Medimetrics S.A. DE C.V, Pentax Medical Company, Boston Scientific Corporation, Bio-Images Research Ltd., and Capsovision, Inc.


The regulation of the medical goods flow as well as services from manufacturer to patient is referred to as healthcare supply chain management. The supply chain is the term used for the resources required to deliver goods or services to a consumer. The management of supply chain in healthcare is characteristically a very complex as well as fragmented process. The health care supply chain consists of three main groups namely, producers, purchasers and providers. The producers include manufacturing companies, purchasers comprises of wholesalers and distributors while providers consist of hospitals, pharmacies, and clinics Presently, the supply chain is facing major hurdles in terms of timely service delivery. It is occurring owing to the fact that every part of it is working independently and not as a collective system, leading to a misaligned network. This has resulted in a variety of solutions to automate as well as streamline the process, grow savings, and decrease costs. The addition of e-commerce solutions results in the omission of error-prone manual processes from the supply chain, leading to huge profits with reduced process costs.

The healthcare supply chain management market can be classified based on delivery model, software, hardware, and geography. Depending on the delivery model, the global healthcare supply chain management market is segmented into cloud-based, web-based and on premise. The market is further segmented by software is segmented into supplier management software, transportation management, procurement software, and others. The hardware market segment is divided into barcode, RFID, systems and others. devices.

The healthcare supply chain management market is analyzed to garner maximum revenue in the forecast period. Factors such as increased focus on supply chain management by the health care industry to efficiently diminish costs, large efforts to deliver high-quality as well as timely services, rising penetration and adoption of different components such as software and cloud-based solutions, and technological advancements leading to automation of the processes are expected to fuel the growth of healthcare supply chain management market.

Based on regions, the global healthcare supply chain management market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is anticipated to command the maximum market share and would lead the market during the forecast period. The presence of top pharmaceutical companies coupled with the several government initiatives, and increased implementation of technologically advanced solutions.

The major companies that provide healthcare supply chain management solutions include SAP AG Group, AmerisourceBergen, Oracle Corporation, Geisinger Health System, Intermountain Healthcare, McKesson Corporation, Providence Health & Services, Advocate Health Care and others. The strategies adopted by the major companies to gain a stronghold in the market include geographical expansion into new, untapped, and potential markets, mergers & acquisitions, and new product launches.


Rising demand for IoT is an vital trend in the global healthcare automation market. With the support of this technology, collecting medical data of patients are easily accessible. However, it supports in improving the health by good quality and accessibility of care and also decreases the costs. Additionally, technology helps inclinical care and remote monitoring. Demand for wearable technology is rising rapidly and is an significant trend in the global market.

The global healthcare automation market has be categorized into application, end-user and regions. Based on application the market has been segmented into therapeutic automation, logistics & training automation, lab& pharmacy automation and diagnostics & monitoring automation. End-user segment has be categorized into pharmacies, home care, research institutes & labs among others.

The major factors driving the healthcare automation market are the growing technological advancements, saving huge cost of labor, and rising the support from government, Implementation of automation is anticipated to reduce the amount of labor-intensive tasks like lab tests and clinical diagnostics, thereby helping hospitals or clinics to save costs pertaining to the processes. Automation permits medical individuals to carry out other significant tasks since it helps in performing repetitive tasks. This is projected to help in carrying out the tasks professionally. These technologies are working to carry out different critical tasks that need accurateness and can be completed through automated machines, which again indicates reduction of overhead counts. The huge initial installation cost is one of the major factors that may hinder the market growth in the near future. Additionally the growing implementation of healthcare automation solutions in various segments is the long-term growth opportunity in healthcare automation market.

Geographically, the healthcare automation market has been bifurcated into five regions North America, Europe, Asia Pacific, Middle East & Africa and Latin America. The Healthcare Automation market size and forecast period for each region has been estimated from 2017 to 2023. Additionally the CAGR (%) for the forecasted period 2017 to 2023. The study also includes market estimates for major countries/regions such as the U.S, the U.K., Germany, France, Japan, China, India, GCC, North Africa, South Africa and Brazil. The detailed analysis by application, end-user, and regions supports in evaluating the present scenario, growth prospects and the future scenario for the healthcare automation market over the forecast period. Thus, the report delivers in-depth segment analysis of the market and classifies it into various industries, thereby providing valuable perceptions.

The rising technological advancements is anticipated to drive the Asia Pacific market for Healthcare Automation in the future years. The major companies that are involved in healthcare automation are General Electric Company, Siemens AG, Swisslog Holdings AG, Intuitive Surgical, Inc., Koninklijke Philips N.V., Medtronic PLC., Tecan Group Ltd., Danaher Corporation, Accuray Inc., and Tecan Group Ltd.


Artificial intelligence (AI) in healthcare uses software and algorithms to estimate human cognition in the analysis of compound medical data. The main aim of health-related AI applications is to examine relationships between prevention nad treatment techniques of patient outcomes. AI programs have been technologically advanced and applied to practices such as treatment protocol development, diagnosis processes, personalized medicine, drug development, and patient monitoring and care, among others. Medical institutions such as, Memorial Sloan Kettering Cancer Center and National Health Service, The Mayo Clinic, multinational technology companies such as Google and IBM, startups such as Ayasdi and Welltok, have created solutions currently used in the industry. Healthcare remains the major area of investment in AI as measured by venture capital deal flow.

Global artificial intelligence in healthcare market has be categorized into offering, technology, application, end-user and regions. Based on the offering the market has been segmented into software, hardware and services. On the basis of technology the Artificial Intelligence in Healthcare market has been divided into deep learning, natural language processing, context-aware processing in querying method. Application segment has been bifurcated into medical imaging & diagnostics, patient data and risk analysis, drug discovery, precision medicine, lifestyle management and monitoring, wearables, virtual assistance, inpatient care and hospital management and research. End-user segment has been categorized into payers, patients, pharmaceutical and biotechnology companies, ACOS & MCOS and providers.

The major factors driving the artificial intelligence in healthcare market are the increasing importance of precision medicine, ability of AI to improve patient outcomes, collaboration of big data in healthcare, rising number of cross-industry partnership and collaborations, growing necessity to reduce increasing healthcare costs, and imbalance between patients and health workforce. Unwillingness among medical practitioners to adopt AI-Based technologies, and ambiguous regulatory guidelines for medical software are the major factors that may hinder the progress of the artificial intelligence in healthcare market in the near future. Additionally the growth opportunities of emerging markets such as India, China, & Brazil and the growth of potential of AI-based tools for elderly care are some of the major growth opportunities for the artificial intelligence in healthcare market players.

Geographically, the artificial intelligence in healthcare market has been bifurcated into five regions North America, Europe, Asia Pacific, Middle East & Africa and Latin America. The Artificial Intelligence in Healthcare market size and forecast period for each region has been estimated from 2017 to 2023. Additionally the CAGR (%) for the forecasted period 2017 to 2023. The study also includes market estimates for major countries/regions such as the U.S, the U.K., Germany, France, Japan, China, India, GCC, North Africa, South Africa and Brazil. The detailed analysis by Offering, Technology, Application and regions supports in evaluating the present scenario, growth prospects and the future scenario for the Artificial Intelligence in Healthcare market over the forecast period. Thus, the report delivers in-depth segment analysis of the market and classifies it into various industries, thereby providing valuable perceptions.

The growing necessity for the reduction in the increasing healthcare costs is anticipated to drive the Europe market for Artificial Intelligence in Healthcare in the future years. The major companies that are involved artificial intelligence in healthcare are Intel Corporation, Google, Inc., NVIDIA Corporation, Microsoft Corporation, IBM Corporation, Enlitic, Inc., General Vision, Inc., iCarbonX, Koninklijke Philips N.V., and Recursion Pharmaceuticals, Inc.


Medical simulation is the modernized methodology of providing training to healthcare professionals with the help of advanced educational technology. To put it in simple words, medical simulation is the practical learning every healthcare professional requires, but cannot always involve in during real-life patient care. The various names used for medical simulation include nursing simulation, healthcare simulation, patient simulation, surgical simulation and clinical simulation.

In the process of medical simulation, the learners are provided with a representative healthcare setting where a reliable patient manikin is wirelessly functioned by both educational as well as simulation technical staff and recorded for playback. The manikin may also be known as nursing simulator, patient simulator, medical simulator, or surgery simulator. During the debriefing process, the patient simulation is digitally streamed live to other learners. The educator provides the patient voice and guides the technical control of the manikin for the entire duration of the experience. The same individual then debriefs the learner as well as rest of the class together with the help of video playback in order to recall performance outcomes.  Actually, the real learning takes place while debriefing process when the group can engage in a facilitated as well as safe conversation in order to find out errors and mark successes.

The global medical simulation market can be classified based on products and services, end user, and region. By products and services, the global market is segmented into web-based simulation, patient simulator, surgical simulator, software, task trainers, dental simulator, and eye simulator. Depending upon end user, the global medical simulation market is divided into academics, hospital, and military.

The global medical simulation market is expected to grow at a fast pace in the forecast period. Factors such as increasing concern about training of medical practitioners, massive healthcare costs, increasing concentration on patient safety, and high demand for minimally invasive technologies are further propelling this market growth.

Based on regions, the global medical simulation market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is anticipated to command the maximum market share and would lead the medical simulation market during the forecast period. The Asia-Pacific as well as Latin American region is expected to register swiftest growth rates in this market owing to the available market potential of these regions and presence of broad customer base owing to the presence of unprecedented aging population, high prevalence of various disorders, and increased demand for surgeries. The medical simulation market in these two regions will be fuelled by developing countries such as South Korea, India, Singapore, China, Brazil, and Mexico.

The global market is of fragmented nature owing to the presence of various small companies operating in their market segments. These small market players are continuously challenging the market share of the prominent players in this market. The major companies that provide medical simulation technology include Laerdal Medical, CAE Healthcare, Simulaids Gaumard, Kyoto Kagako, Limbs and Things, Education Management Solutions and Mentice AB among others.



Digital health is the collaboration of  the genomic and digital evolutions with health, healthcare society, Society healthcare,and living. As we are experiencing, and seeing digital health is allowing us to track better, manage, and improve personal and our family’s health, to live better, more productive lives, and improve society. It’s also helping to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase quality, and make medicine more personalized and precise.

The global market for digital health is evaluated on the basis of the product, component, end user, and the geography. On the bases of product, the market is bifurcated into healthcare information systems and wearable devices. Amongst the two, healthcare information systems leads the global digital health market due to the substantial rise in the implementation of technologically advanced products, such as EHR/EMR, telehealth, and population health management. Additionally, the healthcare information segment is divided into non-clinical solutions and clinical solutions. EHR/EMR, computerized physician order entry (CPOE), Clinical decision support system (CDSS) mHealth, telehealth, and population health management are the major segments of clinical solutions. mHealth is predicted to propel at a suggestively high growth rate on an account of the growing penetration of smartphones across the world and the augmenting levels of consciousness about fitness and health amongst people globally.

Based on the component, the digital health market is bifurcated into hardware, software, and services. The necessity for digital health services is growing when compared to other digital health components and is anticipated to remain highest over the forecast period. On the basis of end users, the market has been segmented into B2C and B2B. The B2B segment has developed as the major contributor to this market over the yeaster years. Providers, payers employers, , and pharmaceutical companies are the main components of the B2B segment, whereas, the B2C segment includes caregivers and patients.

Based on regions, the global Digital Health market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. among these, North America, has been leading the global digital health market. Several factors, such as the prescience of a large pool of players and increasing partnership between them are influential behind the important growth of this regional market. With the high demand from Germany and the U.K., the Europe market for digital health is anticipated to continue on the top position over the next few years. Going onward, Asia Pacific is likely to offer profitable opportunities for the development of the global market for digital health in the forecast period.

Europe commands the second largest share in the global Digital Health market owing to the high expenditures by the European countries such as U. K. Germany among other countries. The major companies that provide Digital Health include Cisco Systems Inc, Agfa-Gevaert N.V., Siemens Healthineers, McKesson Corp., Allscripts Healthcare Solutions Inc., Cerner Corp., Philips Healthcare, GE Healthcare, Epic Systems Corp., Truven Health Analytics, Qualcomm Inc are some of the key players in this market.


Patient registry software is a database that is used to gather data linked to diagnosis or condition of patient, for observing the number of novel medical devices being utilized, or going through novel procedure. The major factors promoting the growth of patient registry software market include high prevalence of chronic disorders, rise in usage of electronic health records (EHRs), rise in government initiatives to construct patient registries and increase in usage of stockpiled data for post-marketing surveillance,. However, shortage of skilled resources and lack of maintenance of vital private data may hamper the market growth. Owing to the increase in accountable care organizations and advent of cloud-based patient registry solutions are expected to offer growth opportunities for this market.

The global patient registry software market can be classified based on deployment model, database, product, functionality, pricing model, end user, and region. On the basis of database, the global market is classified into product registries, health service registries, and disease registries. Depending upon product, it is segmented into integrated as well as standalone software. As per pricing model, it is divided into subscription models and ownership models. Based on deployment mode, it is divided into on-premise and cloud-based models. Based on functionality, it is divided into point of care, product outcome evaluation, health information exchange (HIE), population health management (PHM), patient care management (PCM), and medical research & clinical studies. Depending on end user, it is divided into biotechnology, pharmaceutical, government organizations & third-party administrators; private payers; hospitals & medical practices; and medical device companies; and research centers among others.

Based on regions, the global 3D animation market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The patient registry software providers in North American region gain major demand for their products and services owing to the presence of large number of patients suffering from chronic ailments and the presence of feasible reimbursement policies. Also, majority of the industry players based in North America occupy place in advanced healthcare infrastructure that is ready to implement modern management strategies. The customers present in North American region customers showcase greater rate of awareness towards modernized healthcare trends and the usage of patient registry software. Most importantly, the progression of mHealth trend is propelling the demand for patient registry software in North American region.

Europe also shows similar growth trends trend on a smaller scale. Presence of large number of patients suffering from diabetes, obesity, and other chronic illnesses is fuelling the growth of this market. In the Asia Pacific region, the high population density as well as highly improving healthcare infrastructure is generating a larger scope for global players to enter this market.

The major companies that provide patient registry software include Evado Clinical Solution, Quintiles, Inc., Dacima Software, Inc., PatientCrossroads, and Global Vision Technologies, Inc. among others.

Digital pathology is the most nascent and emerging technology in the pathology sector. In the current methodology, the glass slides that consist of specimen samples are transformed into digital images for easy storage, observance, analysis, and management of the gathered data. This is empowered in part owing to virtual microscopy that is a technology that helps in popular image posting and transmission over a connected network. The data-rich image forms the base for electronic health records maintenance of the patient population and thus compiles the distributed information in order to build up a central database. The technological advancements in digital pathology is anticipated to overtake the traditional pathology to an advanced level. Digitalization of pathology has resulted in the tests automation during diagnosis, thereby saving cost as well as efforts. For instance, a single digital instrument can conduct the tests that were previously conducted using five instruments by pathologists.

The global digital pathology market is segmented on the basis of product, type, end-users and application. By product, the market is classified into scanners, software, communication system and storage systems. Depending on type, the global digital pathology market is classified into human and animal pathology. Based on end-users, the global digital pathology market is divided into pharmaceutical, hospitals and academic agencies. Depending on application, the global market is divided into tele-consultation, and drug discovery. Based on application, the market is subdivided into drug discovery; and teleconsultation.

Digital pathology plays a vital role in companion diagnostics as well as drug development pipeline that includes molecular tissue profiling, molecular biology, biobanking, and tissue microarray analysis. An increase in demand for high-quality tissue samples in tissue-based biomarker research is fuelling the increased rate of adoption of this technology during the forecast period. The global digital pathology market is set to register an intense competition in the future owing to increase in the rate of adoption of rigorous strategies by the market players in order to retain competition.

Based on regions, the global digital pathology market is divided into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. The North American region is anticipated to command the maximum market share and would lead the digital pathology market during the forecast period. Factors such as the rise in chronic disease prevalence and increased number of initiatives by major industry players and government in diagnostics sector are propelling the digital pathology market growth. However, the Asia-Pacific region is expected to exhibit highest growth rate during the future period.

The major companies that provide digital pathology include Hamamatsu Photonics K.K, Leica Biosystems Nussloch GmbH, Definiens AG, Corista LLC, 3D Histech Ltd, Philips Healthcare, Apollo Enterprise Imaging Corp., Xifin, Inc., Visiopharm A/S, Ventana Medical Systems, Inc., Omnyx, LLC., among others.

© Copyright 2017-18 All rights reserved.